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We are all empty houses  
Waiting for someone 
To open the door and set us free. 
 
One day, my wish comes true. 
A man arrives likes a ghost 
And takes me away from my confinement. 
And I follow, whithout doubts, without reserves, 
Until I find my new destiny. 
 
(Director KIM Ki-duk on Bin-Jip) 
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This thesis describes methodological aspects of prognostic classifications in 
oncology, specifically in testicular cancer. This chapter presents issues in the 
development of prognostic classifications, background on testicular cancer and 
the research questions of this thesis. 
 
1.1 Some background on prognostic classifications in oncology 
 
Definition and examples 
The prognosis of a patient with cancer is determined by tumour-, patient-, and 
treatment related factors (Figure 1). Prognosis concerns the further course of 
disease; in oncology it often refers to survival or recurrence of disease 1, although 
the (health related) quality of life is also relevant.  
Tumour related factors include the extent of disease, as measured by size of the 
tumour, spread to lymphatic nodes and spread to other organs (metastases). Such 
characteristics are used in the T(umour) N(ode) M(etastasis) classification system 
to determine the stage of disease. The TNM classification is based on the 
tendency of cancers to start small, enlarge, spread beyond the confines of their 
organs and metastasise first to the lymph nodes and then further via the lymphatic 
system and blood circulation 2, with increasingly poor prognosis.  
Besides factors related to the tumour, patient related factors such as sex, age, co-
morbidity, previous diseases and performance status determine a patient’s 
prognosis. Information on co-morbidity is especially relevant among cancers with 
longer survival such as prostate and breast cancer 3. 
Lastly, treatment affects a patient’s prognosis. Treatment includes surgery (e.g. 
resection of the tumour), chemotherapy, and radiotherapy. The surgical method 
and its successful technical execution (e.g. complete resection) are important for a 
patient’s prognosis. In chemotherapy the agents and doses and the way of 
administration determine prognosis, while for radiotherapy type of radiation, dose 
and volume are relevant. 
It is often useful to group patients with similar characteristics into a prognostic 
classification to support an evidence-based estimate of prognosis and to guide 
individual treatment decisions. 
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Figure 1 The prognosis of a patient with cancer is influenced by characteristics of 
the patient, the tumour and therapy 1 
 
For instance patients with poor prognosis may be considered candidates for more 
intensive treatment strategies, while patients with a good prognosis may be 
treated with less burdensome interventions, for example by less toxic 
chemotherapy regimens 4,5. 
In research, prognostic classifications may be used in the design of randomised 
clinical trials (RCTs) to appropriately target therapies and to increase 
comparability of patients groups across trials. Prognostic classifications can also 
be used for fair comparison of outcome of nonrandomised trials and hospital 
series.  
Prognostic groups may be defined by the number of poor prognostic factors, e.g. 
no poor prognostic factors present (good prognosis) vs. more than one poor 
prognostic factor present (poor prognosis). Alternatively, prognostic factors can 
be combined into a scoring system, in which differences in importance between 
prognostic factors are incorporated by assigning weights to them, e.g. based on 
regression analysis.  
 
 
Chapter 1 
12 
Table 1 Examples of prognostic classification in oncology 
Name 
Type of 
cancer 
Prognostic factors  Type Define groups Use in therapy 
Lymph-node stage Tu Low risk  
Tumour size Tu Medium risk  
Pathological grade Tu High risk 
NPI1 
Breast 
cancer 
   
Adjuvant 
treatment 
      
Serum albumin level Tu   
Hemoglobin level Tu   
Stage IV disease Tu Low risk  
Leukocytosis Tu  
Prevent 
overtreatment 
Lymphocytopenia Tu High risk 
Sex Pt  
Early intensive CT 
+ ASCT 
IPS2 
Advanced 
Hodgkin’s 
disease 
Age Pt   
      
Primary tumour site Tu Good prognosis Lower dose CT 
Tu Inter prognosis Standard CT Non pulmonary visceral 
metastases  Poor prognosis 
Tu 
IGCC3 
Advanced 
testicular 
cancer Tumour markers AFP, 
HCG, LDH  
 
High dose/dose 
intense CT 
      
1 NPI = Nottingham prognostic index (NPI) 
2 IPS = International prognostic factor project 
3 IGCC = International Germ Cell Consensus classification 
CT = chemotherapy 
ASCT = Autologous stem cell transplantation 
Tu = tumour associated factor 
Pt = patient associated factor 
 
Table 1 gives a few examples of prognostic classifications. Researchers of the 
Nottingham City hospital developed the Nottingham Prognostic Index (NPI) for 
women with breast cancer. The NPI uses tumour related factors, namely lymph-
node stage, tumour size and pathological grade, to define high, medium and low 
risk patients. The aim of the classification was twofold; firstly to aid individual 
treatment decisions with respect to adjuvant treatment, and secondly for better 
stratification based on prognosis in the design of clinical trials comparing 
treatment strategies 6.  
The International Prognostic Factors project (IPS) developed a scoring system to 
predict freedom of progression of disease in patients with advanced Hodgkin’s 
disease. Low and high risk patients were defined based on 2 patient related 
factors and 5 tumour related factors to distinguish between high and low risk 
patients. Low risk patients are considered eligible for less intensive treatment to 
prevent overtreatment, while high risk patients might profit from early intensive 
chemotherapy with autologous stem cell transplantation 7. 
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The International Germ Cell Consensus (IGCC) classification, which serves as the 
central case study in this thesis, distinguishes between good, intermediate and 
poor prognosis patients with advanced testicular cancer. It is based on the tumour 
related factors primary tumour site, the presence of metastases and elevated 
tumour markers8. Toxicity in good prognosis patients might be reduced by using a 
relatively low dose of chemotherapy, while survival of poor prognosis patients 
might be improved by using high dose or dose intense chemotherapy. In 
summary, patients with similar tumour- and patient related factors can be grouped 
in a prognostic classification with the aim to guide treatment decisions. 
 
Methodological aspects in defining prognosis groups  
In the prognosis of cancer patients the chance of survival is often the outcome of 
interest. The IGCC classification, for instance has 5-year survival after diagnosis of 
cancer as outcome. Ideally all patients are followed until the outcome of interest 
has or has not occurred, e.g. after 5 years. However, often the outcome is not 
known for all patients. This is also known as ‘censoring’. Censoring can e.g. occur 
because the investigator stopped the study before all patients had at least 5 years 
of follow up, or because the patient was lost to follow up. Survival analysis is 
often used in prognostic studies to appropriately deal with censoring. Survival 
analysis considers the outcome of interest (e.g. death or recurrence) and the time 
to the event of interest (survival time) and takes censoring of patients into 
account. Survival analysis is often reported in terms of survival. The survival 
probability S(t) is the probability that a patient survives from the time of diagnosis 
of cancer to a specified time t, for instance 5 years. Survival probability can be 
estimated using the Kaplan-Meier method. The survival function is defined as 
follows: 
 
S(tj) = S (tj-1) (1- dj/nj) 
 
where the survival probability S(tj) at time t is calculated from S(tj-1) the survival 
probability at time tj-1, nj the number of patients alive just before time tj, and dj the 
number of patients alive just before time tj. The value of S(t) is constant between 
events. Therefore the estimated probability is a step function that only changes 
when an event occurs.  
The Kaplan-Meier method takes censoring into account by allowing each patient 
to contribute information for as long as they are known not to have experienced 
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the outcome. Censoring is assumed to be uninformative, i.e. if patients could have 
been followed beyond the point in time when they were censored, and they 
would have had the same survival probability as those not censored at that time. 
The Kaplan-Meier survival curve plots the survival probability against time and is 
used to compare survival of different patients groups, e.g. according to the 
presence of a prognostic factor. The difference between groups is usually 
assessed with the log-rank test.  
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Figure 2 Kaplan-Meier curves showing the difference in survival between 
nonseminomatous germ cell cancer patients with either testis/retroperitoneum or 
mediastinum as primary tumour site 
 
Figure 2 shows the survival curves for advanced testicular cancer patients having 
either testis/retroperitoneum or mediastinum as primary site, with patients with 
testis as primary site having the better survival. A disadvantage of the Kaplan-
Meier method is that only a limited number, categorical prognostic factors can be 
considered simultaneously. The effect of multiple prognostic factors on survival is 
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usually assessed with the Cox regression model. The Cox regression model is a 
regression model that can estimate the combined effects of categorical and 
continuous prognostic factors on the outcome of interest. 
Survival in the Cox regression model is written as 
 
S(t) = S0(t )
exp(PI) 
 
where S0(t) is the baseline survival probability function and PI the prognostic 
index.  
 
The PI is a linear function of the prognostic factors (x = x1, x2 ….  xk) and the 
regression coefficients (β = β1, β2 …  βk) :  
 
PI = β1 x1 + β2 x2 + … + βk xk 
 
The regression coefficients indicate the size of the effect of the prognostic factors. 
The effects of prognostic factors can be presented as hazard ratios, exp (β). A 
hazard ratio above 1 indicates that a prognostic factor is positively associated 
with the outcome probability, and thus negatively with the length of life.  
Survival curves can also be obtained from a Cox regression model as is shown in 
Figure 3, in which survival of patients with either testis/retroperitoneum or 
mediastinum as primary site are compared. We note that the survival curves 
follow the same pattern as the Kaplan-Meier curves in Figure 2, based on 
assumed proportional hazards of the 2 groups. 
 
Model development  
Prognostic classifications should be based on a heterogeneous and sufficiently 
large sample of patients. To ensure the generalisability of a prognostic 
classification, the sample on which it was based should be representative of a 
wider population of patients. Prognostic classifications should therefore preferably 
be based on patient data from different treatment centres, different treatment 
settings and different regions/countries 9,10. 
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Figure 3 Survival curves based on Cox regression model showing the difference in 
survival between nonseminomatous germ cell cancer patients with either 
testis/retroperitoneum or mediastinum as primary tumour site  
 
Preliminary steps 
When developing a prognostic model a first step is to investigate the candidate 
prognostic factors available in the dataset by studying frequency distributions. This 
also gives insight into the extent of missing values in the data. Often patients with 
missing values on prognostic factors are excluded (complete case analysis). 
However, this is statistically inefficient. Furthermore when the excluded patients 
with missing values differ substantially from patients without missing data, this 
leads to bias 11,12.  
An alternative is to impute missing values with statistical estimates. Imputation 
leads to a complete data set that can then be analysed using statistical methods 
for complete data. A simple method of imputation is the use of the mean or the 
median. A more refined method is to estimate the missing values using regression 
models, exploiting the correlations with other prognostic factors. Such imputation 
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methods have the disadvantage that they do not take the uncertainty of the 
imputation process into account. Imputation methods should include a random 
component to reflect the fact that imputed values are estimated, especially when 
the amount of missing data is substantial. This is taken care of by multiple 
imputation, in which each missing value is imputed several times with different 
plausible value. The variation among the imputations reflects the uncertainty with 
which the missing values can be predicted from the observed ones 12,13.  
A second step is to decide on the coding of categorical prognostic factors. 
Categorical variables may be created from continuous variables (e.g. age < 50 or 
≥ 50). Although such categorisation improves the interpretability of a model, it 
can result in a substantial loss of information 14. Continuous prognostic factors can 
be included as a linear term, which assumes that the relationship with the 
outcome is linear. This assumption can be tested by adding nonlinear terms. 
Examples include simple transformations such as x2, √x, log(x) or exp(x). A more 
efficient, but mathematically more complex method of transforming continuous 
variables is the use of restricted cubic splines 15,16.  
 
Data reduction 
Often, a selection from many potential prognostic factors has to be made to 
derive a practically useful prognostic model. Models with a limited number of 
variables are easier to apply. Also the inclusion of many variables may result in 
fitting specific patterns in the data (‘overfitting’) and therefore a poor performance 
of the model when applied to new patients.  
As a general rule of thumb at least 10 events need to be observed for each 
predictive variable considered 5,15. 
A first selection of variables should be based on expert opinion and previous 
studies. To further limit the number of variables a stepwise selection procedure is 
often used.  
This statistical method considers step by step the additional predictive value of 
variables, by adding (forward stepwise selection) or deleting (backward stepwise 
selection) potential prognostic factors. The variable is selected if the additional 
predictive value is statistically significant, usually using a significance level of 5%. 
Stepwise selection results in models which are easy to interpret as the number of 
prognostic factors is limited. However the use of stepwise selection may lead to 
the exclusion of important prognostic factors. Moreover, the values of the 
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regression coefficients in the selected model are too large, and their uncertainty is 
underestimated (e.g. too small standard error of regression coefficients). 
Once a set of prognostic factors is selected, we need to consider the additivity 
assumption, which is made by most regression models. The additivity assumption 
is that the effect of one prognostic factor does not modify the effect of another 
prognostic factor. This assumption can be tested by including interaction 
terms 17,18.  
 
Alternative models 
Instead of using regression models which assume a linear relationship between 
variables and (a transformation of) outcome, one could also use nonlinear models 
such as recursive partitioning, and neural networks 19,20. 
Recursive partitioning is based on splitting groups of patients into smaller groups 
differing in prognosis. The partitioning algorithm starts with the prognostic factor 
that best discriminates between two groups according to statistical criteria. 
Splitting continues for each subgroup using all available prognostic factors. The 
same prognostic factor may be used more than once. Splitting continues until the 
subgroups reach a specified minimum size or until no further difference in 
prognosis can be made. The use of recursive partitioning directly results in a tree 
with groups differing in prognosis. If the number of identified groups is large, 
groups with similar predicted outcome can be combined.  
Figure 4 shows an example of a regression tree for patients with advanced 
testicular cancer, which uses the prognostic factors visceral metastases, tumour 
location and abdominal metastases to identify 5 groups differing in survival. 
The resulting tree models are attractive because they are easy to apply and 
interpret. They have few restrictions, which makes them suitable for finding 
interactions between prognostic factors. Furthermore trees may show more 
resemblance with the way clinicians make decisions than linear models. On the 
other hand, this flexibility makes trees 'data hungry'. Use of relatively small 
datasets will lead to unstable tree models, and optimism in the performance of 
the model 21,22.  
In artificial neural networks there are some latent, or ‘hidden’ intermediary 
variables between the prognostic factors and the outcome variable. The most 
common model is the three-layer model, in which the prognostic factors (input) 
do not act directly on the outcome variable (output), but channel their influence 
in a series of latent variables. It is the relative importance of these unobservable 
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variables, which determines outcome. An advantage of artificial neural networks is 
that they are very flexible and can include complex relationships between 
prognostic factors and outcome. However, inclusion of complex relationships can 
lead to overfitting, limiting the generalisability to new patients. Furthermore 
artificial neural networks are difficult to interpret, as the importance of prognostic 
factors is often not clear. 
 
|
abdominal metastases
visceral metastases
tumour location tumour location
All
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testis med testis
yes no
med
84%
no
64%
72% 52%
49%
 
 
Figure 4 Example of regression tree obtained through recursive partitioning for 
patients with nonseminomatous germ cell cancer 23  
 
Model performance  
An important aspect of a prognostic classification is its performance, i.e. its ability 
to distinguish between patients with different outcome.  
Differences in survival curves between groups of patients give an important first 
impression. A more formal method is to use an index of concordance, which 
compares predicted survival with observed survival to determine discriminative 
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ability. The value of the concordance measure varies between 0.5 and 1 for 
sensible classifications. 
Alternatively, measures such as the model-chi square, the Brier score and the 
degree of explained variance of the model (R2) can be used.24. 
 
Validation and updating of prognostic classifications 
Before a prognostic classification is applied to newly diagnosed patients it should 
be validated. The prognostic classification might perform well on the data in 
which it was developed, but may be too optimistic for generalisation to other 
settings. Three types of validity can generally be distinguished: apparent, internal 
and external validity. Apparent validity refers to the performance of a model on 
the patients in which the model was developed. Internal validity refers to the 
performance of a model in a population of similar patients. There are several 
methods of assessing internal validity. A method that is often used is split sample, 
in which e.g. 2/3 of the data are used for the development of the model and 1/3 
for validation. Drawbacks of this method are that sample size is limited for both 
model development and model validation and that due to chance, substantial 
differences could occur between the development and the validation set. More 
efficient are crossvalidation methods or resampling techniques such as 
bootstrapping 25. With bootstrapping random samples are drawn with 
replacement from the data. These bootstrap samples are similar in structure to the 
original data. Each bootstrap sample is representative of the underlying 
population from which the original dataset was drawn. In each bootstrap sample 
the development process of the model is repeated and then evaluated in the 
original data. The difference in performance between the development and 
testing situations indicates the degree of optimism. 
External validity refers to the performance of a model in new patients, differing for 
instance in time, setting or region of treatment 26. An external validation study 
may show that patient outcome has improved over time, e.g. because of 
improved treatment strategies. This may motivate an update of a prognostic 
classification. 
 
Prognostic groups from Cox models 
To define prognostic groups cutoffs can be applied to the prognostic index (PI) 
from a Cox regression model. Groups can be made based on percentiles of 
patients (e.g. 10% patients with lowest predicted probability), optimisation of 
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model performance (maximising a chi-square statistic over different cutoffs of the 
PI) or maximising the difference in patient outcome between groups (separation 
of survival curves). 
Ideally cutoffs are based on decision analytic techniques in which the expected 
gain in survival due to treatment (benefit) and the burden (harm) due to treatment 
are weighed to determine at what risk which treatment might be beneficial.  
Ideally benefit is based on results from RCTs. 
The optimal cutoff point is where the benefit of treatment equals the harm of 
treatment. Patients whose risk of cancer mortality is above the threshold should 
be treated with the alternative treatment, while patients with a risk below the 
threshold should receive standard treatment. 
 
Examples  
Table 2 summarises the methodological aspects of the examples presented in 
table 1.  
The Nottingham prognostic index was constructed with Cox regression analysis 
on 387 patients, because of missing values in 113 patients. Based on the results of 
Cox regression analysis a simplified prognostic index was proposed and cutoffs 
determined based on stratification of patients using only lymph-node stage. This 
model has later been validated and modified, identifying three prognosis groups 
differing in survival 6,27. 
The International prognostic factor project also used Cox regression analysis to 
identify seven prognostic factors for patients with advanced Hodgkin disease 7. 
Prognosis groups differing in survival were identified based on the number of 
adverse prognostic factors present. Although 5141 patients from 25 centres were 
available only 1618 patients were included in the final analysis due to missing 
data. Internal validation was done on a subset of 2643 patients with incomplete 
data. 
The IGCC classification dismissed 2154 of 5202 patients due to missing values. 
Prognostic factors were identified using Cox regression analysis. Prognosis groups 
were defined by the presence of good, intermediate or poor prognostic factors 
but not by the number of prognostic factors. Hence, effectively a ‘max function’ 
was applied. The IGCC classification was both internally and externally validated 8.  
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Table 2 Methodological aspects of examples of prognostic classifications in 
oncology 
Name 
Type of 
cancer 
Patients Missing 1 Model Weights 
Definition 
groups 
Validation 
NPI2 
Breast 
cancer 
500 113 
Cox 
regression 
Simplified 
regression 
weights 
Cutoffs on 
prognostic 
index 
external 
        
IPS3 
Advanced 
Hodgkin 
disease 
5141 3253 
Cox 
regression 
Equal 
weights 
Number of 
adverse 
prognostic 
factors 
internal 
        
IGCC4 
Advanced 
testicular 
cancer 
5202 2154 
Cox 
regression 
Simplified 
regression 
weights 
Max function 
on number of 
adverse 
prognostic 
factors 
internal 
and  
external 
1 Number of patients excluded because of missing values 
2 NPI = Nottingham prognostic index (NPI) 
3 IPS = International prognostic factor project 
4 IGCC = International Germ Cell Consensus classification 
CT = chemotherapy 
ASCT = Autologous stem cell transplantation 
 
1.2 Defining prognosis groups in advanced testicular cancer 
 
Clinical background advanced testicular cancer  
Although testicular cancer accounts for only 1% of all cancers in men, it is the 
most common cancer in young adult men 26. An estimated 8000 new cases of 
testicular cancer occurred in 2005 in the US 26. In 1998 there were 482 new 
cases in the Netherlands 28.  
Germ cell tumours account for 95% of testicular cancer, with 10% of all germ cell 
tumours arising from extragonadal primary sites, such as the mediastinum and 
retroperitoneum. Germ cell tumours are distinguished according to histology in 
seminomas and nonseminomas. A tumour is diagnosed as a seminoma if the 
tumour contains pure seminomatous tissue and the serum level of alpha-
fetoprotein, a marker of nonseminomatous tumours, is normal. Non-
seminomatous tumours consist of any combination of embryonal carcinoma, 
teratoma, choriocarcinoma, yolk sac, or seminoma cell types.  
After diagnosis of testicular cancer treatment usually starts with orchidectomy to 
remove the primary tumour. Further treatment depends on clinical staging which 
is determined by assessments of primary tumour, lymph node, the presence of 
distant metastasis and tumour markers alpha-fetoprotein (AFP), human chorionic 
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gonadotrophin (HCG) and lactate dehydrogenase (LDH). When disease is limited 
to the testis, epididymis, or spermatic cord, this is labelled stage I disease. When 
distant disease is suspected, further treatment may consist of chemotherapy or 
retroperitoneal lymph node dissection (RPLND) 29. Approximately 30% of patients 
with stage I disease have occult metastatic disease detected at RPLND or 
surveillance. Since many predictors of occult metastatic disease are known 
various simple classification schemes are available to select patients for more 
intensive treatment 30. Advanced disease includes metastases in the regional 
nodes (stage II), and the presence of distant metastasis or elevated serum tumour 
markers (stage III) and is treated with chemotherapy or resection of residual 
masses 31,32. 
Since the 1970s long term cure rates of patients with advanced germ cell tumours 
have increased to over 80%, because of the ability of cisplatin-based 
chemotherapy to cure advanced disease 33-36. Because of the high overall cure 
rate, interest has shifted from increasing the overall cure rate to reducing 
treatment related toxicity for patients with a good prognosis 37. On the other hand 
poor prognosis patients should be identified, who are eligible for new treatment 
regimens such as dose-intensification and high-dose chemotherapy with stem cell 
support 38,39. 
 
Methodological aspects in defining prognosis groups in advanced  
testicular cancer: an historical overview  
Several prognostic studies had been conducted before the IGCC classification to 
identify groups of patients with nonseminomatous germ cell cancer that differ in 
prognosis (Table 3). These studies established that prognosis is not only related to 
anatomic spread of disease, but also to the primary site (extragonadal or gonadal) 
and to the extent of production of the serum tumour markers AFP, HCG, LDH. 
Bosl and colleagues (1983) used a logistic regression model to predict the 
probability of complete response (CR) of 171 patients treated at the Memorial 
Sloan Kettering cancer center (MSKCC) 40. The total number of metastatic sites 
and pretreatment levels of tumour markers LDH and HCG were the most 
important prognostic factors, which predicted response correctly for 83% of 
patients. Patients with a predicted probability ≥ 0.5 were considered as good 
prognosis, while patients with a predicted < 0.5 were considered as poor 
prognosis. The predictive ability has been supported by the results of 300 patients 
treated in trials conducted by the MSKCC since 1982. CR rates were 51 and 40% 
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in two poor risk trials and 96 and 93% in a randomised trial comparing treatments 
for good risk patients. The prognostic importance of tumour markers LDH and 
HCG and the number of metastatic sites has been confirmed in an additional 100 
patients 41. 
 
Table 3 Overview of prognostic models developed to classify advanced testicular 
cancer patients before the IGCC classification 
Name 
(year) 
N Statistical 
model 
Prognostic factors Prognosis groups n outcome 
Log (AFP) MSKCC 
(1983) 
171 Logistic 
regression Log (LDH) 
Good p(CR) > 0.5 136 84% CR 
   Total number of 
metastases 
Poor p(CR) < 0.5 35 20% CR 
        
Indiana staging 
system 
Good minimal and 
moderate 
51 96% CR Indiana 
(1986) 
137 Logistic 
regression 
Elevated tumour 
markers 
Poor advanced 86 58% CR 
        
Presence 
trophoblastic 
elements primary 
tumour 
Good high p(CR) 97 89-100% 
CR 
AFP ≥1000 ng/ml Inter inter p(CR) 46 41% CR 
Presence lung 
metastases 
EORTC 
(1987) 
154 Logistic 
regression 
Size and number of 
lung metastases 
Poor low p(CR) 11 18% CR 
        
Liver, bone or brain 
metastases 
AFP > 1000 kU/L or 
HCG > 1000 IU/L 
Good no adverse 
prognostic 
factors 
528 92% OS 
Mediastinal mass   
> 5 cm 
MRC 
(1992) 
795 Cox 
regression 
model 
> 20 lung metastases 
Poor ≥ 1 adverse 
prognostic 
factor 
267 68% OS 
        
MSKCC = Memorial Sloan Kettering Cancer Center 
EORTC = European Organisation for Research and Treatment of Cancer 
MRC = Medical Research Council 
p(CR) = probability of complete response; OS = overall survival 
Indiana staging system: minimal: elevated HCG or AFP, cervical nodes, unresectable, but nonpalpable 
disease, minimal pulmonary disease; moderate: palpable abdominal mass only, moderate pulmonary 
metastases; advanced: advanced pulmonary metastases, palpable abdominal mass plus pulmonary 
metastases, hepatic, osseous, or CNS metastases 
 
 
The Indiana University system also used logistic regression to extend the Indiana 
staging system which classifies patients as having minimal, moderate or advanced 
disease 42. Fifty-one patients with minimal or moderate disease had a response 
rate of 96% and formed the good prognosis group. The group of 86 patients with 
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advanced diseases had a response rate of 58%. The number of elevated tumour 
markers further subdivided this group into subgroups with estimated response 
rates of 73, 65 and 45%. 
The European Organisation for Research and Treatment of Cancer (EORTC) 
identified three prognostic groups (n=154) using the prognostic factors presence 
of trophoblastic elements in primary tumour, the value of AFP, presence of lung 
metastases and the size and number of lung metastases using logistic regression. 
The definition of good, intermediate and poor prognosis groups was based on the 
probability of a CR. 
The models developed by the MSKCC, Indiana University and the EORTC each 
have some disadvantages. First, the generalisability of these models was limited 
because of the small number of patients in all three studies, and because of the 
homogeneity of the group of patients in the studies by MSKCC and Indiana 
University (single center cohorts). Furthermore all three studies used CR as 
outcome instead of the more informative outcome, survival.  
The Medical Research Council Working Party on Testicular Cancer was the first to 
combine individual patient data of different treatment centres. They analysed 
survival of 458 patients treated between 1976 and 1982 at six British centres. 
With the prognostic factors tumour volume, degree of elevation of tumour 
markers AFP and HCG three prognosis groups were identified with 3-year survival 
of 91, 74 and 47% respectively 43. 
This study was succeeded by the Second Medical Research Council study, which 
assessed prognosis in a more recent treatment era (1982-1986). Individual patient 
data treated in 13 centres in the UK and Norway were combined resulting in a 
large and heterogeneous database of 795 patients 44. 
Using Cox regression analysis they selected the prognostic factors presence of 
liver, bone or brain metastases, AFP ≥ 1000 kU/L and/or HCG ≥10.000 IU/L, 
mediastinal mass more than 5 cm and more than 20 lung metastases on which a 
simple prognostic classification was based. Good prognosis patients (n=528) had 
no adverse prognostic factors and a 5-year survival of 92%. Poor prognosis 
patients (n=267) had one or more adverse prognostic factor and a 3-year survival 
of 68%. 
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The IGCC Classification: methodological merits and limitations  
The coexistence of classifications differing in type, complexity and ability to 
separate good from poor prognosis complicated international collaboration in 
randomised trials and made comparison of nonrandomised studies impossible. 
Therefore the International Germ Cell Cancer Collaborative Group (IGCCCG) 
was formed which resulted in the development of the International Germ Cell 
Consensus Classification (IGCC classification) 8. 
The IGCCCG analysed data from previously conducted trials from the British 
Medical Research Council (MRC), the EORTC, groups from the United States 
(MSKCC, New York, NY; Indiana University Hospital; University of Texas MD 
Anderson Cancer Center), and national germ cell groups from Canada, Australia, 
New Zealand, Spain, France, Denmark, and Italy.  
Patients participating in these trials had either nonseminomatous (n=5202) or 
seminomatous (n=660) germ cell cancer and were treated between 1975 and 
1990. All patients were treated with cisplatin- (or carboplatin-) containing 
chemotherapy. Five readily available prognostic factors were selected from a 
wider set following Cox regression analyses. The site of primary tumour was 
categorised as testis or retroperitoneal vs. mediastinal. The presence of non-
pulmonary visceral metastases (NPVM) was defined as disease at any 
nonpulmonary visceral site (liver, bone, brain, kidney, skin or gastrointestinal). The 
pretreatment levels of tumour markers alpha-fetoprotein (AFP), human chorionic 
gonadotrophin (HCG) and lactate dehydrogenase (LDH). AFP and HCG were 
analysed as ratios more than each institution’s upper limit of normal. Due to 
interlaboratory variations in assays, LDH levels were considered only as ratios, 
formed by dividing absolute values by the upper limit of the normal range for 
each institution. The tumour markers were categorised into three categories 
(good, intermediate, poor).  
The prognostic factors were combined into three prognostic groups for patients 
with nonseminomatous germ cell tumours (NSGCT) with either good, 
intermediate or poor prognosis (Table 4). The good prognosis group was 
characterised by the absence of adverse prognostic factors, the intermediate 
prognosis group by the presence of any intermediate tumour marker, and the 
poor prognosis group by the presence of any of the poor prognostic factors 
mediastinal primary site, NPVM, AFP poor, HCG poor or LDH poor. The 
classification can be seen as a max function where the good, intermediate and 
poor prognosis groups have a maximum score of zero, one or two respectively.  
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Figure 5 Survival of patients with nonseminomatous germ cell cancer from the 
IGCCC database, with either good, intermediate or poor prognosis 
 
In the published report 56, 28 and 16% of patients were allocated to the good, 
intermediate and poor prognosis groups, with a 5-year survival of 92, 80 and 48% 
respectively (Figure 5) 8. For patients with seminomatous germ cell tumours only a 
good and intermediate prognosis group were identified. They represent 90% and 
10% of seminomas respectively and have a 5-year survival of 86 and 72%. Good 
prognosis was defined as any primary site, no NPVM and normal tumour markers, 
while intermediate prognosis is defined as any primary site, the presence of 
NPVM and normal tumour markers. 
The IGCC classification has quickly become the standard for the design and 
selection of patients for RCTs and the analysis of observational studies, such as 
Phase I/II trials and hospital series. The findings of the IGCCCG have been 
incorporated into the AJCC staging system for testicular cancer, extending the 
TNM system to a TNMS system including serum tumour markers. 
The IGCC classification has several advantages over its predecessors. The 
international collaboration of several research groups resulted in a heterogeneous 
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study population with thousands of patients. The use of patient data of several 
institutions and countries ensures the generalisability of the IGCC classification.  
The selection of prognostic factors was based on previous studies and analysis 
was performed on a sufficiently large sample size. This resulted in a classification 
with a limited number of well-established prognostic factors, also identified in 
previous studies. 
 
Table 4 The International Germ Cell Consensus (IGCC) Classification 8 
GOOD PROGNOSIS 
NONSEMINOMA SEMINOMA 
Testis/retroperitoneal primary site 
And 
No nonpulmonary visceral metastases 
And 
AFP good and HCG good and LDH good 
 
56% of nonseminomas 
5 year PFS 89% 
5 year OS 92% 
Any primary site 
And 
No nonpulmonary visceral metastases 
And 
Normal AFP, any HCG, any LDH 
 
90% of seminomas 
5 year PFS 82% 
5 year OS 86% 
INTERMEDIATE PROGNOSIS 
NONSEMINOMA SEMINOMA 
Testis/retroperitoneal primary site 
And 
No nonpulmonary visceral metastases 
And 
AFP intermediate or HCG intermediate or LDH 
intermediate 
 
28% of nonseminomas 
5 year PFS 75% 
5 year OS 80% 
Any primary site 
And 
Nonpulmonary visceral metastases 
And 
Normal AFP, any HCG, any LDH 
 
10% of seminomas 
5 year PFS 67% 
5 year OS 72% 
POOR PROGNOSIS 
NONSEMINOMA SEMINOMA 
Mediastinal primary site 
Or 
Nonpulmonary visceral metastases 
Or 
AFP poor or HCG poor or LDH poor 
 
16% of nonseminomas 
5 year PFS 41% 
5 year OS 48% 
No patients classified as poor prognosis 
Tumour markers alpha-fetoprotein (AFP)/ human chorionic gonadotrophin (HCG)/lactate 
dehydrogenase (LDH): Good - AFP < 1000 ng/ml, HCG < 5000 iu/l, LDH < 1.5 x upper limit of 
normal; Intermediate - AFP 1000 – 10000 ng/ml, HCG 5000 - 50000 iu/l, LDH 1.5 - 10 x N; Poor - 
AFP > 10000 ng/ml, HCG > 50000 iu/l,  LDH > 10 x N 
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The IGCC classification has some limitations. The IGCC classification did not 
consider differences in importance between intermediate tumour markers and 
differences in importance between poor prognostic factors. Furthermore no 
distinction is made between the number of intermediate tumour markers in the 
intermediate prognosis group and the number of poor prognostic factors in the 
poor prognosis group. Better discrimination might be achieved by incorporating 
differences in predictive strength and testing specific interaction terms. 
All prognostic factors included in the IGCC classification had missing values, 
especially the tumour marker LDH (37%). Data analysis was performed on 3048 
complete cases, discarding data of 2154 patients. Exclusion of patients because of 
missing data was statistically inefficient, and could have led to bias in the survival 
estimates of the prognostic groups in the IGCC classification.  
The survival estimates of the IGCC classification were based on patients treated 
between 1975 and 1990. Some patients, treated before 1985, were treated with 
carboplatin containing chemotherapy, which is now considered inferior to 
cisplatin containing chemotherapy. Survival may have increased since 1990 due 
to further improvements in treatment strategies. The survival estimates of the 
IGCC classification may therefore not be generalisable to patients diagnosed 
nowadays.  
The group of poor prognosis patients is especially of interest, since their survival 
could be improved by alternative, more intensive treatment strategies such as 
high-dose chemotherapy with stem cell support or dose intensification. 
Further subgrouping of poor prognosis patients would allow for a more precise 
identification of individuals patients at high risk, and the use of risk-adapted 
treatment strategies.  
The German Testicular cancer group developed a regression tree model to 
identify subsets of patients within a group of poor prognosis patients, as defined 
by the IGCC classification, treated in three clinical trials (n=332). Three subgroups 
were identified with 2-year survival varying from 49% to 84% 23. Validation of this 
model in a different group of patients is necessary before this model can be used 
in clinical practice and the design of clinical trials. 
The criteria used to define ‘poor prognosis’ in the IGCC classification were 
prognosis (a low estimated survival) and sample size (a large enough group for 
clinical trials). Ideally, when considering a more intensive treatment the toxic side 
effects or burden due to this treatment (‘harm’) should also be taken into account 
and weighed against the expected gain in survival (‘benefit’). By specifying harm 
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and benefit of a treatment, treatment cutoffs can be determined through decision 
analysis. 
 
1.3 Research questions 
 
In this thesis we study methodological aspects of defining prognosis groups. We 
use the IGCCC classification for nonseminomatous germ cell cancer for 
illustration. 
Firstly we evaluate the validity of the IGCC classification; is the model underlying 
the classification correctly specified or can performance be improved, and can the 
survival estimates be generalised to newly diagnosed patients. Secondly, we look 
at alternative ways of defining prognostic groups; we specifically look at poor 
prognosis patients, as this group has most to gain from alternative treatment 
strategies.  
 
Validity of the IGCC classification 
1. Are the assumptions made in the development of the IGCC classification 
valid with regard to the inclusion of prognostic factors, or can discriminative 
ability be improved? 
The IGCC classification considers all prognostic factors to be equally important, 
and makes no distinction between number of prognostic factors within a 
prognosis group. Incorporating differences in importance and number of 
prognostic factors may result in better discriminative ability (Chapter 2).  
 
2. What is the effect of missing values on survival estimates of the IGCC 
classification? 
In the IGCC classification many patients had missing values, and they were 
excluded from analysis. Currently imputation techniques are available to more 
appropriately deal with this problem (Chapter 3). 
 
3. Has survival of patients with advanced testicular cancer improved since the 
introduction of the IGCC classification? 
The IGCC classification included patients treated between 1975 and 1990, and 
updating of estimates may be necessary (Chapter 4). 
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Definition of the poor prognosis group for advanced testicular cancer 
4. Is regression tree analysis an appropriate method for further subgrouping 
within poor prognosis patients? 
Further subgrouping within the poor prognosis group has been considered with 
regression tree analysis, but the validity of this subgrouping needs further study 
(Chapter 5). 
 
5. At what risk of cancer-mortality should patients with advanced testicular 
cancer be treated with high-dose chemotherapy? 
In the IGCC classification, the creation of prognostic groups was loosely based on 
percentiles of prognosis, with 16% labelled ‘poor prognosis patients’ being 
candidates for more intensive therapy, and 56% labelled ‘good prognosis 
patients’ being candidates for less intensive therapy. Decision-analytic approaches 
need to be considered for better support of cutoffs in the IGCC classification 
(Chapter 6). 
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Abstract 
 
Background The International Germ Cell Consensus (IGCC) classification 
identifies good, intermediate and poor prognosis groups among patients with 
metastatic nonseminomatous germ cell tumours (NSGCT). It uses the risk factors 
primary site, presence of nonpulmonary visceral metastases and tumour markers 
alpha-fetoprotein (AFP), human chorionic gonadotrophin (HCG) and lactate 
dehydrogenase (LDH). The IGCC classification is easy to use and remember, but 
lacks flexibility. We aimed to examine the extent of any loss in discrimination 
within the IGCC classification in comparison with alternative modelling by formal 
weighing of the risk factors. 
Methods We analysed survival of 3048 NSGCT patients with Cox regression and 
recursive partitioning for alternative classifications. Good, intermediate and poor 
prognosis groups were based on predicted 5-year survival. Classifications were 
further refined by subgrouping within the poor prognosis group. Performance was 
measured primarily by a bootstrap corrected c-statistic to indicate discriminative 
ability for future patients. 
Results The weights of the risk factors in the alternative classifications differed 
slightly from the implicit weights in the IGCC classification. Discriminative ability, 
however, did not increase clearly (IGCC classification, c=0.732; Cox classification, 
c=0.730; Recursive partitioning classification, c=0.709). Three subgroups could be 
identified within the poor prognosis groups, resulting in classifications with five 
prognostic groups and slightly better discriminative ability (c=0.740).  
Conclusion In conclusion, the IGCC classification in three prognostic groups is 
largely supported by Cox regression and recursive partitioning. Cox regression 
was the most promising tool to define a more refined classification. 
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2.1 Introduction  
 
Testicular germ cell tumours (seminomatous and nonseminomatous) are the most 
common cancers among young adult men. Since the 1970s, long term cure rates 
of patients with germ cell tumours have increased to over 80%, because of the 
ability of cisplatin-based chemotherapy to cure advanced disease 1-4. Owing to the 
high overall cure rate, interest has shifted from increasing the overall cure rate to 
reducing treatment-related toxicity for patients with a good prognosis 5. On the 
other hand, high risk patients, eligible for more intensive treatment, for example, 
stem cell support or high-dose chemotherapy, should be identified 6,7. 
Several classifications have been proposed in the past to distinguish patients 
according to prognosis, by identifying and combining the main prognostic factors 
for progression-free survival (PFS) and overall survival 8-10. The coexistence of 
classifications differing in type, complexity and ability to separate good from poor 
prognosis complicated international collaboration in randomised trials and made 
comparison of nonrandomised studies impossible. International collaboration by 
the International Germ Cell Cancer Collaborative Group resulted in the 
development of the International Germ Cell Consensus Classification (IGCC 
classification), which is widely applied and easy to use and remember 11. 
For the IGCC classification, readily available risk factors were selected from a 
wider set following Cox regression analyses, namely primary site, presence of 
nonpulmonary visceral metastases (NPVM) and elevation of the tumour markers 
alpha-fetoprotein (AFP), human chorionic gonadotrophin (HCG) and lactate 
dehydrogenase (LDH). All variables were categorical, since no major differences 
in performance were found compared to using continuous variables 12. In Table 1, 
how the risk factors were combined into three prognostic groups for patients with 
nonseminomatous germ cell tumours (NSGCT) with either good, intermediate or 
poor prognosis are shown. The good prognosis group is characterised by the 
absence of adverse risk factors. The intermediate prognosis group is defined by 
the presence of any intermediate tumour marker, that is, one or more 
intermediate tumour markers are present. The poor prognosis group is 
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characterised by the presence of any of the poor risk factors mediastinal primary 
site, NPVM, AFP poor, HCG poor or LDH poor, that is, one or more poor risk 
factors are present. The classification can be seen as a max function where the 
good, intermediate and poor prognosis groups have a maximum score of zero, 
one or two, respectively. 
In the IGCC classification, all intermediate tumour markers and all poor risk 
factors were required only to be sufficiently bad to be classified as intermediate 
and poor prognosis, respectively, that is, differences in importance between 
intermediate tumour markers and differences in importance between poor risk 
factors are not taken into account. Furthermore, no distinction is made between 
the number of intermediate tumour markers in the intermediate prognosis group 
and the number of poor risk factors in the poor prognosis group. Better 
discrimination might be achieved by incorporating differences in predictive 
strength and testing specific interaction terms.  
Furthermore, it is difficult to adjust the current classification for changes in 
treatment strategy. A more flexible scoring system could more easily identify 
subgroups for the identification of very high risk patients eligible for novel 
chemotherapy approaches such as high-dose chemotherapy or the use of novel 
cytotoxic agents 6,13. We however note that an important consideration in 
developing the IGCC classification was that all the prognostic groups should be 
large enough to make randomised trials of new treatments for each prognostic 
group feasible 11. 
The aim of this study was to reconsider steps taken in the development of the 
IGCC classification, and to investigate alternative classifications based on Cox 
regression and recursive partitioning 14 that may discriminate better and be more 
suitable to identify more subgroups. 
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Table 1 The International Germ Cell Consensus 
(IGCC) Classification 15 
GOOD PROGNOSIS 
NONSEMINOMA 
Testis/retroperitoneal primary site = 0 
And 
No nonpulmonary visceral metastases = 0 
And 
AFP good = 0 and HCG = 0 good and LDH good = 0 
 
Max = 0 
INTERMEDIATE PROGNOSIS 
NONSEMINOMA 
Testis/retroperitoneal primary site = 0 
And 
No nonpulmonary visceral metastases = 0 
And 
AFP intermediate =1 or HCG intermediate =1 or LDH 
intermediate =1 
 
Max = 1 
POOR PROGNOSIS 
NONSEMINOMA 
Mediastinal primary site =2  
Or 
Nonpulmonary visceral metastases =2 
Or 
AFP poor = 2 or HCG poor =2 or LDH poor =2 
 
Max = 2 
Tumour markers alpha-fetoprotein (AFP)/ human chorionic 
gonadotrophin (HCG)/lactate dehydrogenase (LDH): Good - 
AFP < 1000 ng/ml, HCG < 5000 iu/l, LDH < 1.5 x upper limit of 
normal; Intermediate - AFP 1000 – 10000 ng/ml, HCG 5000 - 
50000 iu/l, LDH 1.5 - 10 x N; Poor - AFP > 10000 ng/ml, HCG 
> 50000 iu/l,  LDH > 10 x N 
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2.2 Materials and methods 
 
Patients 
Centres participating in the International Germ Cell Collaborative Group provided 
retrospective data of 5202 adult male patients with NSGCT. All patients were 
treated between 1975 and 1990 with cisplatin-based chemotherapy. Data were 
collected on age, primary site, date of diagnosis, levels of serum AFP, HCG and 
LDH, nodal disease in the abdomen, mediastinum, and neck, lung metastases, 
spread to other visceral sites like liver, bone and brain and on treatment details 
like previous therapy. For the development of the IGCC classification, patients 
without missing data on the risk factors primary site, NPVM, tumour markers AFP, 
HCG and LDH and the outcome survival were selected (n=3048) 11. 
 
Outcome and IGCC risk factors 
The outcome measures were PFS and overall survival from the start of the 
chemotherapy. The risk factors in the IGCC classification were primary site 
(testis/retroperitoneal vs. mediastinum), presence of NPVM (yes/no) and tumour 
markers AFP, HCG and LDH. Each tumour marker had three categories; good, 
intermediate and poor with specific cutoff points on the continuous tumour 
markers (see Table 1) 11. The same risk factors and categories were used to 
construct the alternative classifications based on Cox regression and recursive 
partitioning. 
 
Statistical analyses 
The IGCC classification makes no clear distinction between the intermediate 
tumour markers and between the poor risk factors and is represented by a max 
score. One way to assess this assumption is by evaluating whether the weights in 
the IGCC classification were optimally allocated to the risk factors. We hereto 
varied the IGCC weights (1/2) over the levels of the risk factors and compared all 
possible combinations with respect to performance. Performance was quantified 
by the difference in minus twice the log likelihood (model χ2) 16.  
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We used the Cox regression to study the univariable and multivariable effects of 
the IGCC risk factors on the overall survival, expressed as Hazard ratios and 
regression coefficients. 
The Cox regression model formed the basis of classification '5R'. We multiplied 
the multivariate regression coefficients by 10 and rounded them to obtain 
weights. A sum score was calculated by multiplying the weights with individual 
patient characteristics and adding the resulting individual scores 17. We calculated 
the estimated 5-year survival rate for each score. 
The IGCC classification can be viewed as implying that the risk factors are 
strongly dependent, that is, that there are interactions between risk factors. There 
is, for example, no distinction made between patients with one poor risk factor or 
three poor risk factors. To test whether and which interactions were present, we 
added all two-way interactions between the IGCC risk factors in a Cox regression 
model. Important interactions were selected through stepwise backward selection 
(P<0.05). Since interactions based on small number of patients give unreliable 
regression coefficients, the interaction terms were defined as linear. The resulting 
model forms the basis of classification '5Ri'. A sum score based on a regression 
model with interactions is, however, more difficult to calculate and interpret. 
Therefore, a table was constructed with 5-year survival estimates for all possible 
combinations of the IGCC risk factors based on the Cox regression model with 
linear interactions. The number of patients on which each survival estimate was 
based is given to indicate the reliability of the survival estimates. 
An alternative and visually more attractive way of exploring and presenting 
interactions between risk factors is by growing a tree through recursive 
partitioning 14,18,19 that we used to construct classification '5T'. A binary tree is built 
by the following process: first the risk factor that best splits the data into two 
groups, leading to the largest decrease in prediction error, is determined 
(recursive partitioning or splitting method). Splitting continues until the subgroups 
reach a minimum size or until no improvement can be made (stopping rule). The 
full tree, which is often too complex and overfit, is pruned using crossvalidation. 
All trees within one standard error of the lowest crossvalidated prediction error 
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are considered as equivalent. From these equivalent trees, the simplest is chosen 
as final tree 14. 
As a splitting method, the exponential scaling method was used 20,21. The splitting 
process stopped when a minimum of five patients per groups was reached or 
when there was no further decrease in prediction error. We used 10-fold 
crossvalidation to determine the optimal tree size. Modelling was performed with 
S-plus version 2000 using the RPART library that contains a recursive partitioning 
method for survival data.  
The RPART library (rpart2.zip) and manual (rpart2doc.zip) can be found at 
http://www.stats.ox.ac.uk/pub/SWin. 
 
Prognostic groups 
In all classifications, three prognostic groups were identified using the estimated 5-
year survival by sum score (classification 5R), combination of risk factors (5Ri) or 
binary tree (5T). Subgroups with a 5-year survival higher than 90% were 
considered as good prognosis, between 65 and 89% as intermediate prognosis, 
and lower than 65% as poor prognosis. 
Furthermore for each classification, we explored the possibility of identifying more 
subgroups. For the IGCC classification, this was carried out by allowing weights to 
vary from zero to four (instead of zero to two), and comparing all possible 
combinations on performance. For classifications 5R, 5Ri and 5T, we changed the 
cutoff points on estimated 5-year survival. A 5-year survival rate higher than 90% 
was considered as good prognosis, 75-89% as intermediate prognosis, 60-74% as 
good-poor prognosis, 40-59% as intermediate-poor prognosis, and lower than 
40% as poor-poor prognosis 13. Survival of the five groups of the IGCC 
classification and classifications 5R, 5Ri and 5T was presented by Kaplan-Meier 
curves. 
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Performance 
The classifications were evaluated by their ability to distinguish between patients 
differing in survival. An indication of the discriminative ability is the difference in 5-
year survival rates between the good, intermediate and poor prognosis groups. A 
c-statistic was also calculated for both the three and five group classifications. For 
binary outcomes, the c-statistic is similar to the area under the ROC curve 22. The 
c-statistic for survival data indicates the probability that for a randomly chosen pair 
of patients, the one having the higher predicted survival is the one who survives 
longer 22. Overall performance of the three and five group classifications was 
measured by model χ2. When a model is developed and evaluated on the same 
data, the performance of the model is usually too optimistic. The optimism can be 
quantified with statistical methods, known as internal validation techniques 23.To 
estimate and correct for the optimism in discriminative ability, the steps taken in 
the Cox regression and recursive partitioning were internally validated by taking 
random bootstrap samples (100) 24,25. 
 
2.3 Results  
 
The median follow up time of surviving patients was 50 months. Disease 
progression occurred in 680 patients, and 533 patients died. The 5-year PFS was 
78% (95% CI 76-79%) and the 5-year overall survival 82% (95% CI 81-84%). 
Most patients had as primary site testis or retroperitoneum (97%), no NPVM 
(92%), and good AFP, HCG and LDH levels (84, 87 and 67%, respectively) (Table 
2). All risk factors were predictors of survival as indicated by the Hazard ratios 
ranging from 2.1 to 6.2, where the tumour marker AFP was the weakest risk factor 
in the univariable analysis. 
 
Alternative classifications 
The regression-based weights of the risk factors in classification 5R, and the cutoff 
points on the resulting sum score are presented in Table 3, with the weights and 
cutoff points of the IGCC classification. 
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Table 2 Characteristics of 3048 NSGCT patients on the IGCC risk factors 
IGCC risk factors Number of 
patients (%) 
5-year 
survival  
95% CI HR 95% CI 
Primary site       
   Testis/ Retroperitoneal 2947 (97) 84% 82-85% 1 - 
   Mediastinum 101 (3) 37% 27-47% 6.1 4.7-7.9 
NPVM       
   No 2808 (92) 85% 84-86% 1 - 
   Yes 240 (8) 49% 42-55% 4.6 3.8-5.6 
AFP       
   Good  2559 (84) 85% 84-87% 1 - 
   Intermediate 349 (12) 71% 66-76% 2.1 1.7-2.6 
   Poor 140 (5) 56% 47-65% 3.6 2.7-4.7 
HCG       
   Good  2656 (87) 86% 84-87% 1 - 
   Intermediate 238 (8) 65% 58-71% 3.0 2.3-3.8 
   Poor 154 (5) 48% 39-56% 5.0 3.9-6.4 
LDH       
   Good  2036 (67) 89% 88-91% 1 - 
   Intermediate 977 (32) 68% 65-71% 3.3 2.8-3.9 
   Poor 35 (1) 51% 34-67% 6.2 3.9-10.1 
Total number subjects 3048 (100) 82% 81-84% - - 
NPVM = nonpulmonary visceral metastases 
 
The weights suggest that differences between risk factors were present. Tumour 
marker AFP had a much lower weight in the multivariate analysis than tumour 
markers HCG and LDH. As a result, a poor AFP level (score 3) is not sufficient to 
be classified as poor prognosis in classification 5R. Also, the combination of two 
or three intermediate tumour markers, which would lead to an intermediate 
prognosis in the IGCC classification, results in a score of over 10 and thus in 
classification in the poor prognosis group in classification 5R. The presence of risk 
factor NPVM (score 7) alone was not sufficient to be classified as poor prognosis, 
in contrast with the IGCC classification. Patients would only be classified as poor 
prognosis when other risk factors besides NPVM or AFP are present. 
We identified four significant interactions in the Cox regression model; between 
AFP and primary site (P<0.001), AFP and NPVM (P<0.01), HCG and NPVM 
(P<0.003) and HCG and LDH (P<0.01). The regression coefficients all had 
negative signs, indicating that the effect of the risk factors together was smaller 
than the sum of their separate effects. For all 108 combinations of the IGCC risk 
factors, we present 5-year survival estimates from the Cox regression model with 
interactions (Appendix). Patients with testis as primary site and good or 
intermediate tumour markers had the highest estimated survival (55-92%).  
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Table 3 Weights, coding of variables, and cutoff on the max function of the 
IGCC classification and the sum score of the regression-based classification 
5R 
Classification IGCC  5R 
Risk factors in the 
model 
Coding of risk factors implicit weights regression 
weights 
Testis/ retroperitoneal 0 0 Primary site 
Mediastinum 2 15 
    
No 0 0 NPVM 
Yes 2 7 
    
Good 0 0 
Intermediate 1 2 
AFP  
Poor 2 3 
    
Good 0 0 
Intermediate 1 9 
HCG  
Poor 2 11 
    
Good 0 0 
Intermediate 1 7 
LDH  
Poor 2 9 
    
Good Max 0 Sum 0 
Intermediate 1 2-10 
Cutoff points 
Poor ≥2 ≥11 
NPVM = nonpulmonary visceral metastases 
 
Patients with mediastinum as primary site and NPVM had the worst estimated 
survival (0-64%). Since the number of patients with more than one poor risk 
factor was limited, the survival estimates for these patients were less reliable. 
Recursive partitioning resulted in a tree with seven subgroups with 5-year survival 
ranging from 35 to 91% (Figure 1), forming the basis of classification 5T. Tumour 
marker LDH was the principal determinant of 5-year survival, making a split 
between good LDH (N=2036) and intermediate/poor LDH (N=1012). The 
majority of the 'good LDH' subgroup consists of patients with no risk factors 
(N=1865) with an observed 5-year survival of 91% (95% CI 90-93%). 
Furthermore, a subgroup of 29 patients with primary site mediastinum had a 5-
year survival of 55% (95% CI 34-72%) and patients with intermediate or poor 
HCG (N=142) had a 5-year survival of 70% (95% CI 61-77%). Within the 
subgroup intermediate/poor LDH, four further subgroups were identified with the 
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risk factors NPVM, primary site and HCG, with 5-year survival ranging from 35 to 
80%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The final tree fitted by recursive partitioning, using the exponential 
scaling method. The 5-year survival rates, events and total number of observations 
per subgroup are given. The resulting subgroups are displayed in rectangulars and 
determine classification 5T 
 
Performance  
The 5-year survival rates for the good, intermediate and poor prognosis groups 
were comparable for the IGCC classification and classifications 5R, 5Ri and 5T 
(Table 4). The c-statistic of the IGCC classification was 0.732. The apparent c-
statistics of classifications 5R, 5Ri and 5T were 0.732, 0.735 and 0.718, 
respectively. Validation showed minor optimism in the c-statistic in the Cox 
regression models (0.002). More optimism was present in the classification 5T, 
with the c-statistic decreasing from 0.718 to 0.709. Classification 5R did not show 
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an improvement in model χ2 compared to the IGCC classification (model χ2 402 
and 401, respectively, 2 d.f.). Classifications 5Ri did show a statistically significant 
increase in overall performance over the IGCC classification (model χ2 422, 2 
d.f.). Classification 5T had a worse overall performance with a model χ2 of 374 (2 
d.f.). 
 
Identification of more subgroups 
Within the max score, different weights did not lead to an improvement in overall 
performance over the weights of the IGCC classification (model χ2 402, 2 d.f.). 
The following weights were allocated to derive a max function with five 
prognostic groups in the IGCC classification with the score varying between 0 
and 4; primary site mediastinum (4), NPVM (3), AFP good/intermediate/poor 
(0/1/2), HCG good/intermediate/poor (0/2/3) and LDH good/intermediate/poor 
(0/1/3). The 5-year survival varied from 37 to 92% for the five groups of the IGCC 
classification, from 34 to 92% for classification 5R, from 36 to 92% for 
classification 5Ri and from 35 to 91% for classification 5T (Table 5). The cutoff 
points on the sum score for the five groups of classification 5R are also given in 
Table 5. The difference in survival between the prognostic groups for each 
classification is illustrated in Figure 2. The c-statistic for the five groups of the 
IGCC classification and classifications 5R and 5Ri was slightly higher than for the 
three group classifications (0.739, 0.741 and 0.744, respectively) and with a small 
amount of optimism (0.002) for the Cox regression models. The increase of the c-
statistic for the five groups of classification 5T was very limited (0.722) with an 
optimism of 0.011. The increase in model χ2 was more substantial; 422 for the 
extended IGCC classification, 446 for classification 5R, 450 for classification 5Ri. 
The increase in model χ2 for classification 5T (383) was less substantial. 
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Table 4 Survival of the IGCC classification, the regression-based 
classifications 5R and 5Ri and classification 5T based on recursive 
partitioning 
 IGCC  5R  5Ri  5T 
Group Surv N  Surv N  Surv N  Surv N 
Good 92% 1691  92% 1691  92% 1691  91% 1865 
Intermediate 81% 862  80% 872  80% 915  78% 761 
Poor 50% 495  50% 485  47% 442  49% 422 
Surv=5-year survival 
 
 
Table 5 Survival of subgroups within the IGCC classification, the regression-
based classifications 5R and 5Ri and classification 5T based on recursive 
partitioning 
 IGCC  5R  5Ri  5T 
Group (Surv) Surv N  Surv N  Surv N  Surv N 
Good (≥ 90%) 92% 1691  92% 1691  92% 1691  91% 1865 
Intermediate (75-89%) 82% 684  81% 824  82% 818  80% 619 
Good-poor (60-74%) 72% 251  65% 225  63% 194  70% 142 
Intermediate-poor (40-59%) 51% 321  48% 169  51% 188  51% 376 
Poor-Poor (≤40%) 37% 101  34% 139  36% 157  35% 46 
Surv=5-year survival 
Cutoff points on sum score classification 5R: Good 0, Intermediate 2-9, Good-poor 10-16, 
Intermediate-poor 17-22, Poor-poor > 22 
 
A Methodological Review of the IGCC Classification  
 
49 
2.4 Discussion 
 
The discriminative ability of classifications derived through Cox regression and 
recursive partitioning was in concordance with the IGCC classification and 
therefore supports the validity of the IGCC classification. We did, however, find 
that not all intermediate tumour markers and poor risk factors were equally 
important, and that taking these differences into account does affect the 
classification of patients. In Cox regression-based classifications, especially risk 
factors NPVM and AFP had less impact compared to the other risk factors. That 
AFP is of less importance than the other risk factors is confirmed by recursive 
partitioning where AFP was not selected in the final tree. Furthermore, not all risk 
factors had statistical interactions. In classifications 5Ri and 5T, only a limited 
number of interactions were included. Combining several risk factors led to 
differences in 5-year survival, that is, patients with one poor risk factor had a 
better chance of survival than patients with three risk factors. These deviations 
from the weights used by the IGCC classification did, however, not lead to 
improvements in discriminative ability, in contrast with what we expected. The 
use of Cox regression and recursive partitioning did allow for more flexible 
classifications with more subgroups, leading to a small improvement in 
discriminative ability and 5-year survival of 34% for the poorest risk patients. 
It appears that the maximum discriminative ability might have been reached with 
the current IGCC risk factors and coding, making further improvement in 
discriminative ability difficult. The risk factors selected for the IGCC classification 
are in agreement with risk factors used in other studies on identifying good and 
poor prognosis patients with NSGCT 8,10. Some other potentially useful risk factors 
include age, lung metastases and abdominal mass size. However, adding these 
three risk factors to the Cox model had no substantial effect on discriminative 
ability (c increased from 0.73 to 0.74). One could also consider using continuous 
codings of tumour markers, but this would lead to an undesirable increase in 
complexity and decrease in applicability. 
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The division into more prognostic groups is similar to another division by 
recursive partitioning of poor prognosis patients13. Kollmannsberger et al 
identified three prognosis groups: a good-poor, intermediate-poor and poor-poor 
risk group with 2-year survival rates of 84, 64 and 49%, respectively. These 
survival rates are higher than the survival rates of the good-poor, intermediate-
poor and poor-poor risk groups identified in the IGCC dataset. This may be due to 
the difference in survival for the poor prognosis patients (72 vs 50%), and remains 
when the difference in follow up time is taken into account (2 vs 5 years). The 
data in Kolmannsberger et al (2000) are more recent and improvements in 
treatment may have led to the difference in survival. 
The lack of improvement in discriminative ability in both the classifications with 
three and five groups might also be explained by the dominance of the good 
prognosis group, which has a similar survival for all classifications and contains 
more than half of all patients. We therefore examined whether discriminative 
ability increased within the poor prognosis group of each classification. 
Discriminative ability increased from 0.50 to 0.60, 0.63, 0.64 and 0.65 for the 
three poor prognosis groups of classifications 5T, IGCC, 5R and 5Ri, respectively. 
Hence, some improvement was noted within the IGCC poor prognosis group. 
Furthermore, even though the c-statistic is often used and easy to interpret, it is 
not suitable for detecting small differences in discriminative ability 25,26.  
Although the use of Cox regression and recursive partitioning did not have a 
major effect on discriminative ability, they can still be useful tools in the 
construction of future prognostic classifications when other criteria are taken into 
account. One of the advantages of classifications such as the IGCC classification 
is its simplicity. Classification 5T is reasonably simple with only a few subgroups 
and the survival probability readily available. Classification 5R is slightly more 
complicated because of the sum score that has to be calculated. Finally, 
classification 5Ri is not so much complicated as visually unattractive. Furthermore, 
survival estimates for infrequent combinations of risk factors are not reliable and 
therefore provide little information on the prognosis of patients with these risk 
factors. 
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Figure 2 Survival curves for the 5 groups of the IGCC classification (a) and 
classifications 5R (b), 5Ri (c) and 5T (d) 
 
A disadvantage of the IGCC classification is its inflexibility. More groups could be 
defined, but not in a straightforward manner. Classification 5R and classification 
5Ri are very flexible with many possible cutoff points. Classification 5T is less 
flexible due to the limited number of subgroups, but flexibility could be increased 
by putting fewer restrictions on the recursive partitioning allowing for more 
subgroups to be identified. 
The IGCC classification considered not just discrimination but also simplicity and 
the size of the resulting prognostic groups and was chosen by consensus from a 
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shortlist of possible models, which balanced these considerations. Consequently, 
in the IGCC classification there is a lack of transparency; it is unclear how the 
classification was constructed statistically because statistical considerations were 
not the only criteria used to derive the classification. Classification 5T shows very 
clearly how the subgroups were derived from the successive splits in the risk 
factors. Classification 5R shows the difference in importance between the risk 
factors and how the risk factors are combined in a sum score. Classification 5Ri 
could be presented in a similar way as classification 5R, but interpretation of the 
main and interaction effects is difficult. 
The IGCC dataset suffers from a number of limitations. First, not all data were 
used for the multivariable regression models because of missing data. When 
patients with missing data differ from the other patients on prognosis, this causes 
a bias in the regression coefficients and the estimated 5-year survival rates 27-29. 
Secondly, we could not internally validate the IGCC classification, because the 
exact steps taken in the modelling process (selection and categorisation of risk 
factors) were not defined. The IGCC classification was applied to a 30% 
validation set 11, and although the proportion of patients in each prognostic group 
was similar, the 5-year survival for poor prognosis patients was higher (57%). We 
did internally validate the modelling steps of the Cox regression models and found 
minor optimism in discriminative ability. Classification 5T, based on recursive 
partitioning, however, showed optimism in discriminative ability, as might be 
expected from a more data-driven method. This, in combination with the poorer 
performance, suggests that recursive partitioning is less suitable for the 
construction of prognostic classifications. It can be useful, however, for 
exploratory analyses in finding interactions between risk factors. 
The survival estimates of the IGCC classification were also externally validated 
with more recent data from an MRC/EORTC trial (N=300). The 2-year PFS 
outcome largely corresponded with the IGCC estimates 11. To gain further insight 
in the generalisability of the Cox regression models as well as the IGCC 
classification, further external validation is necessary, in larger recent datasets with 
longer follow up.  
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In conclusion, the IGCC classification appears to be a valid way to classify 
patients with NSGCT in three prognostic groups. Recursive partitioning is less 
suitable for the construction of prognostic classifications, because of its poorer 
performance. Although Cox regression did not lead to a clear improvement in 
performance, it gave a more flexible and transparent scoring system without 
much loss in simplicity. We therefore recommend the use of regression-based 
weights in the development of future prognostic classifications. 
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Appendix 
 
5-year survival estimates and number of patients are given for all 108 
combinations of the IGCC risk factors based on a Cox regression model of 
the IGCC risk factors and interactions AFP and primary site, AFP and 
NPVM, HCG and NPVM, and HCG and LDH 
    Primary site   Primary site  
   Testis Mediastinum 
   NPVM NPVM NPVM NPVM 
AFP HCG LDH No Yes No Yes 
   Surv N Surv N Surv N Surv N 
  Good 92% 1691 79% 27 53% 14 18% 1 
 Good Inter 83% 459 60% 31 25% 12 2% 10 
  Poor 73% 11 43% 3 10% 0 0% 1 
  Good 77% 81 54% 9 15% 3 1% 0 
Good Inter Inter 66% 62 38% 16 5% 1 0% 1 
  Poor 60% 2 30% 0 2% 0 0% 0 
  Good 64% 16 39% 8 4% 0 0% 0 
 Poor Inter 59% 56 32% 38 2% 1 0% 2 
  Poor 61% 0 35% 3 3% 0 0% 0 
  Good 88% 121 79% 5 65% 8 44% 1 
 Good Inter 76% 104 60% 18 39% 14 17% 6 
  Poor 64% 0 43% 1 21% 0 5% 0 
  Good 69% 16 54% 1 28% 0 12% 0 
Inter Inter Inter 55% 19 37% 9 13% 0 3% 0 
  Poor 48% 1 30% 3 8% 0 2% 0 
  Good 52% 2 38% 1 11% 0 4% 0 
 Poor Inter 46% 13 32% 3 7% 0 2% 0 
  Poor 49% 3 35% 0 9% 0 3% 0 
  Good 81% 16 76% 5 71% 4 64% 1 
 Good Inter 63% 43 55% 24 48% 17 38% 3 
  Poor 47% 2 37% 3 30% 0 20% 0 
  Good 54% 4 49% 0 37% 0 32% 0 
Poor Inter Inter 37% 10 31% 0 20% 0 16% 0 
  Poor 29% 0 21% 0 14% 0 10% 0 
  Good 33% 0 33% 1 17% 0 17% 0 
 Poor Inter 27% 1 26% 3 12% 1 12% 0 
  Poor 30% 0 29% 2 15% 0 14% 0 
Surv= 5-year survival 
N = number of patients 
Inter = Intermediate 
Classification into 3 groups; Good prognosis 5-year survival >90%, Intermediate prognosis 5-year 
survival 65-89%, Poor prognosis 5 year survival <65%. 
Classification into 5 groups; Good prognosis 5-year survival >90%, Intermediate prognosis 5-year 
survival 75-89%, Good-poor prognosis 5 year survival 60-74%, intermediate-poor prognosis 5 
year survival 40-59%, Poor-poor prognosis 5 year survival <40% 
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Abstract 
 
Background The International Germ Cell Consensus (IGCC) classification defines 
good, intermediate, and poor prognosis groups among patients with 
nonseminomatous germ cell cancer. In the database used to develop the IGCC 
classification (n = 5202), >40% of patients were excluded because of missing values 
(n = 2154). We looked for effects of this exclusion on survival estimates in the three 
IGCC prognosis groups. 
Methods We imputed missing values using a multiple imputation procedure. The 
IGCC classification was applied to patients with complete data (n = 3048) and with 
imputed data (n = 2154), and 5-year survival was calculated for each prognosis 
group. 
Results Patients with missing values had a lower 5-year survival than those without 
missing values: 76 vs. 82%. Five-year survival in the complete and imputed data 
samples was 92 and 87% for the good prognosis groups and 80 and 70% for the 
intermediate prognosis groups, whereas 5-year survival for the poor prognosis 
groups in both samples was similar (50 and 47%, respectively). This difference in 
survival was largely explained by a higher proportion of missing values among 
patients treated before 1985, who had a worse survival than patients treated after 
1985. 
Conclusion Multiple imputation of the missing values led to lower survival estimates 
across the IGCC prognosis groups, compared with estimates based on the 
complete data. Although imputation of missing values gives statistically better 
survival estimates, adjustments for year of treatment are necessary to make the 
estimates applicable to currently diagnosed patients with testicular cancer.  
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3.1 Introduction 
 
Testicular germ cell tumours (seminomatous and nonseminomatous) are the most 
common cancers among young adult men. Since the 1970s, long term cure rates of 
patients with germ cell tumours have increased to >80%, because of success of 
cisplatin-based chemotherapy in curing advanced disease 1-4. Toward defining 
prognosis groups, the International Germ Cell Cancer Collaborative Group 
(IGCCCG) combined data from 5202 patients with nonseminomatous germ cell 
tumours (NSGCT). This resulted in the International Germ Cell Consensus (IGCC) 
classification, which identifies three prognosis groups - good, intermediate, and poor 
- based on five easily measured risk factors: primary site, presence of nonpulmonary 
visceral metastases (NPVM), and levels of the tumour markers alpha-fetoprotein 
(AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) 5,6. 
In the published report, 56, 28, and 16% of patients were allocated to the good, 
intermediate, and poor prognosis groups, with a 5-year survival of 92, 80, and 48%, 
respectively 5. The IGCC classification is widely accepted and easy to use and 
remember. 
Because only patients with complete data were considered, however, the data for 
2154 patients were excluded, and the IGCC classification was based on roughly 
3000 patients, not the full dataset of ~5000 patients. Wherever the patients with 
missing values differ substantially from patients without missing values, this could 
have led to bias in the survival estimates of the prognostic groups in the IGCC 
classification. Furthermore, exclusion of patients because of missing data is 
statistically inefficient 7. It would therefore be preferable to estimate the missing 
values and use all available data instead of excluding patients with missing values. 
The IGCC classification was published in 1997 5. Since then, application of methods 
for handling missing data is becoming more standard and software is more readily 
available. Multiple imputation (MI) is considered a sound statistical methodology for 
handling complex missing data problems 7-9; its use is not widespread, however, and 
the implications of using MI are still unclear. We studied the effects of MI on 
survival estimates in the three IGCC prognosis groups. We also tried to explain 
possible differences between patients with and without missing values, and the 
implications for the clinical applicability of the IGCC classification. 
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3.2 Patients and methods 
 
Patients 
Centres participating in the International Germ Cell Collaborative Group provided 
retrospective data of 5202 adult male patients with NSGCT. All patients were 
treated between 1975 and 1990 with cisplatin-based chemotherapy. Data were 
collected on age, histology, primary site, date of diagnosis, treatment centre, levels 
of tumour markers AFP, HCG, and LDH, the presence and the size of nodal disease 
in the abdomen, mediastinum, and neck, the presence, number and size of lung 
metastases, spread to other visceral sites such as liver, bone and brain, previous 
radiotherapy, and prior node dissection 5.  
 
Outcome and risk factors 
The outcome measures were overall survival and progression-free survival from the 
start of chemotherapy, and response to treatment (complete, incomplete, or not 
assessable). We focus on overall survival in our analysis. The risk factors in the IGCC 
classification were primary site (testis or retroperitoneal vs. mediastinum), presence 
of NPVM (yes or no), and tumour markers AFP, HCG, and LDH. Each tumour 
marker was categorized as good, intermediate, or poor, with specific cutoff points 
for each marker based on a previous study on the prognostic value of tumour 
markers (see footnotes to Table 2) 5,10.  
Some variables considered potentially related to the presence of missing values 
were not included in the IGCC classification: age, histology, abdominal mass, 
mediastinal mass, and presence of metastases in neck and lung. Furthermore, 
treatment variables not considered risk factors could also be related to missing 
values: year of treatment, region of treatment centre, previous radiotherapy (yes or 
no), and prior node dissection (yes or no) 5,7. Centres were classified into four 
regions; North America (the United States and Canada), the United Kingdom, 
Europe, and Oceania (Australia and New Zealand). 
 
Multiple imputation 
Imputation is the replacement of missing data with statistical estimates. The goal of 
imputing missing values is to produce a complete dataset that can then be analysed 
using statistical methods for complete data. Examples of imputation techniques 
include mean imputation, regression imputation, and hot deck 11,12.  
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A disadvantage of these imputation methods is that they do not take the uncertainty 
of the imputation process into account. Imputation methods should include a 
random component to reflect the fact that imputed values are estimated. This will 
be especially relevant when the amount of missing data is substantial. 
In multiple imputation (MI), each missing value is imputed several (M) times, with 
the imputed values drawn from their predictive distribution. The variation among 
the M imputations reflects the uncertainty with which the missing values can be 
predicted from the observed ones. MI results in M complete datasets, which can be 
analysed with standard complete data methods. The results are then combined to 
produce overall estimates and standard errors that reflect missing data uncertainty 
7,9,13,14. MI assumes that the missing data are missing at random (MAR). This means 
that the probability of a missing value depends only on other observed variables. 
This assumption implies that the missingness of a variable does not depend on 
unobserved variables, nor on the true unobserved value of the variable itself—in 
which case the missing values would be missing not at random (MNAR) 15. 
We applied the multiple imputation procedure according to Van Buuren et al 7. This 
is a semiparametric approach in which each variable has a separate imputation 
model, with a set of predictors explaining missingness and the form (e.g., predictive 
mean matching, logistic) of the imputation model depending on the type of variable 
(e.g., continuous, binary). To estimate values for the missing data, the Van Buuren 
approach does not explicitly assume a particular form for the multivariate 
distribution. It does assume that a multivariate distribution exists and that draws can 
be generated from it by Gibbs sampling of the conditional distributions, based on 
the imputation models. Gibbs sampling is a Monte Carlo technique to simulate 
drawings from a multivariate probability density distribution by repeatedly drawing 
from conditional probability density distributions 16. This is an iterative process in 
which the missing values of a variable are estimated using its imputation model, and 
the completed variables are used to estimate the missing values for the other 
variables - also called regression switching. Each iteration ends when all variables 
have been updated 7,13.  
We followed three main steps to investigate the missing data and apply the multiple 
imputation procedure: (a) investigate missing data; (b) specify the imputation 
models by risk factor; and (c) generate sets of imputed values to obtain the desired 
number of completed datasets. 
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The first step, investigation of missing data, was conducted as follows: 
1. Quantify the multivariate patterns of the missing data - how many patients are 
missing in each IGCC risk factor. 
2. Check whether there is a difference in survival between patients with and without 
missing values. 
3. Investigate for differences in measuring practice over time and region - the 
proportion of missing data for each risk factor against year of treatment for each 
region. 
4. Explore the relationship between missing values of the IGCC risk factors and 
other risk factors and treatment variables using correlation coefficients. 
 
Correlation coefficients were obtained by univariate logistic regression taking the 
square root of the explained variance (R2). 
In the second step, we specified an imputation model for each IGCC risk factor, 
according to the guidelines in Van Buuren et al 7. All five risk factors from the IGCC 
classification and the outcome variables were included. We included those 
treatment variables related to missingness. We also included risk factors related to 
the value of the variable to be imputed. The form of the imputation model was 
chosen depending on the type of variable. For the continuous variables (age, AFP, 
HCG, LDH), a predictive mean matching model was used as the imputation model. 
This imputes a missing value by selecting at random, with replacement, a value from 
those individuals who have matching observed values for other variables. We used 
a logistic regression model for the binary variables (primary site, NPVM, abdominal 
mass, mediastinal mass, presence of metastases in neck and lung, prior 
radiotherapy, prior node dissection) and a polytomous regression model for the 
categorical variables (histology and response to treatment). The log-transformed 
tumour markers AFP, HCG, and LDH were imputed as continuous variables, and 
then categorized according to the cut-points specified in the IGCC classification. 
Finally, we used the imputation model to generate 10 sets of imputed values for the 
missing data, which resulted in 10 versions of completed datasets. The Gibbs 
sampling algorithm was run for 20 iterations, with updating for each of the 10 sets 
of imputed values. Simulation studies have shown that as few as 10 iterations are 
usually sufficient to obtain convergence 7. 
When 50% of the data are missing, an estimate based on M = 5 imputations has a 
standard deviation that is only 5% wider than an estimate based on an infinite 
number of imputations. Therefore, 5–10 imputations are usually sufficient 14. 
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Statistical Analyses  
Patient characteristics on the IGCC risk factors and the IGCC classification are given 
for the samples with complete data (n = 3048) imputed data (n = 2154), and all data 
(n = 5202). We report the imputed data separately, to evaluate the effects of 
imputation without dilution in all data. The frequencies of the IGCC risk factors in 
imputed and all-data samples were obtained by averaging the frequencies over the 
10 datasets 14. In each dataset, the difference in frequencies between the complete 
and the imputed data was tested using a chi-square statistic. We averaged the 10 
chi-square statistics to determine the overall difference in frequencies. The number 
of patients and 5-year overall survival was studied for each prognosis group and 
compared in the complete, imputed, and all-data samples. Five-year overall survival 
was calculated by the Kaplan–Meier method in each dataset and then averaged 
over the 10 datasets. Differences in survival between the complete and imputed 
data in each dataset were tested using a log-rank test. We averaged the log-rank 
statistics of each of the 10 datasets to determine the overall difference in survival 
between complete and imputed data. 
The IGCC classification was evaluated in the complete, imputed, and all-data 
samples on its ability to distinguish between patients differing in survival. 
Discriminative ability was indicated by a c-statistic. For binary outcomes, the c-
statistic is similar to the area under the receiver operating characteristic (ROC) 
curve. The c-statistic for survival data indicates the probability that, for a randomly 
chosen pair of patients, the one having the higher predicted survival is the one who 
survives longer 17. The c-statistic was determined for the complete data and in each 
imputed and all-data dataset. We took the average of the c-statistics in the 10 
datasets for the imputed data and for all data. The variance of this overall c-statistic 
is the average variance over the 10 datasets plus the variance between datasets. We 
used this overall variance to determine the 95% confidence interval CI of the c-
statistics of the imputed and all-data samples. 
To better compare the value of the c-statistic in the imputed data with the c-statistic 
in the complete data, the expected value of the c-statistic in the imputed data was 
calculated. This c-statistic was obtained by combining the average proportion of 
patients in the prognosis groups in the 10 imputed datasets with the survival 
estimates of the prognosis groups in the complete data in a simulated sample of 
10000 patients drawn with replacement. 
Finally, we did a pooled Cox regression analysis on the 10 datasets to explain 
possible differences between patients with and without missing values 13. Hazard 
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ratios were determined for each dataset and averaged over the 10 datasets. The 
variance of the overall hazard ratio is the average variance over the 10 datasets plus 
the variance between datasets 13.  
All statistical analyses were done in S-Plus 2000 (Mathsoft, Inc, Seattle, WA) using 
the Hmisc, Design, and MICE libraries. MICE is available from www.multiple-
imputation.com. 
 
3.3 Results 
 
Follow up information was available on all 5202 patients. The median follow up 
time of surviving patients was 5 years, and 90% had been followed for at least 2 
years from the start of chemotherapy. Disease progression occurred in 1313 
patients, and 1056 patients died. Five-year progression-free survival was 75% (95% 
CI = 74–76%) and 5-year overall survival was 80% (95% CI = 79–81%). 
 
Missing data 
Of the IGCC risk factors, LDH had the most missing values: 1945 (37%). The 
number of missing values in the other IGCC risk factors was limited; 53 (1%) in 
primary site, 185 (4%) in NPVM, 114 (2%) in AFP, and 91 (2%) in HCG (Table 1). 
These 2388 missing values represent only 9% of all 26010 possible data values (5 
risk factors × 5202 patients), but resulted in the exclusion of 2154 (41%) of 5202 
patients in the development of the IGCC classification. Of the 2154 patients, 1979 
(92%) had only one missing value, 124 (6%) had two missing values, 44 (2%) had 
three missing values, 6 (<1%) had four missing values, and 1 (<1%) patient had all 
five IGCC risk factors missing. Patients with missing values (n = 2154) had a lower 5-
year overall survival than patients without missing values (n = 3048); 76% (95% CI = 
74–78%) vs. 82% (95% CI = 81–84%) (Figure 1, P < .001). 
There were differences in measuring practice of tumour marker LDH over time and 
across treatment centre regions (Figure 2). The proportion of missing LDH values in 
North American centres was small and constant over time (average 8%).  
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Figure 1 Survival and number of patients at risk for patients with and without 
missing values for the risk factors of the IGCC classification. Error bars indicate 95% 
confidence interval 
 
In European centres, initially half of the LDH values were missing, but after 1982 the 
proportion of missing values decreased to 10%; on average, 14% of LDH values in 
European centres were missing. Most missing LDH values were in centres from the 
United Kingdom (73%) and Oceania (87%). The proportion of missing LDH values 
decreased over time in the United Kingdom, but it stayed more or less constant in 
Oceania. The other IGCC risk factors showed no differences in measuring practice 
over time or across regions. 
In Table 1, correlation coefficients are shown between missingness and the value of 
LDH on the one hand and several risk factors, outcome, and treatment variables on 
the other hand. 
Year of treatment and region of treatment centre were most strongly related to the 
presence of missing LDH values, with correlation coefficients of 0.29 and 0.61, 
respectively. Except for the risk factors age and prior radiotherapy, all variables were 
significantly related to the value of LDH. All 18 variables were included in the 
imputation model. This imputation model was used for all variables with missing 
values. 
Chapter 3 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Number of missing and measured values of tumour marker LDH per year 
per region. Black bars represent the number of patients with LDH missing; grey 
bars, the number of patients with LDH not missing. By region, the number of 
patients with (without) LDH values are: (a) North America, n = 1163 (n = 96); (b) 
Europe, n = 1615 (n = 270); (c) United Kingdom, n = 411 (n = 1130); and (d) 
Oceania, n = 68 (n = 449) 
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Table 1 Variables considered for imputation with number of missing values 
and their correlation with log of the LDH value and with missingness of 
LDH 
  r  
Variables Missing  values, 
no. (%) 
 LDHvalue LDHmissing 
     
IGCC risk factors      
    Primary site  53  (1) .08** .06** 
    NPVM  185  (4) .29** .03 
    AFP  114  (2) .19** .04 
    HCG  91 (2) .25** .04 
    LDH  1945  (37)   -   - 
     
Outcome variables     
    Survival time in months  0  (0) .13** .14** 
    Dead  0  (0) .25** .05** 
    Response to treatment  392  (8) .23** .08** 
     
Other risk factors     
   Age  62  (1) .00 .04** 
   Histology  54  (1) .05* .07** 
   Abdominal mass   142  (3) .18** .02 
   Mediastinal mass  111  (2) .21** .06** 
   Neck mass  180  (4) .25** .02 
   Lung metastases  111  (2) .19** .00 
     
Treatment variables     
   Year of treatment  0  (0) .05* .29** 
   Prior radiotherapy  1097  (21) .01 .13** 
   Prior node dissection  1740  (33) .13** .12** 
   Region1 0  (0) .10** .61** 
AFP, alpha-fetoprotein; HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; 
NPVM, nonpulmonary visceral metastases. Tumour markers AFP, HCG, LDH according to IGCC 
classification. 
* P < .05; 
** P < .01. 
a Regions were North America (United States and Canada), Europe, United Kingdom, and 
Oceania (Australia and New Zealand) 
 
Distribution of IGCC risk factors and the IGCC classification 
We completed 10 datasets, imputing 2388 values in each dataset. As a result, 8382 
real data values could be added into each dataset (2154 patients with missing 
values × 5 risk factors - 2388 = 8382). In Table 2, the distribution of patients over 
the IGCC risk factors in the complete data (n = 3048), imputed data (n = 2154) and 
all-data (n = 5202) samples is given. There were significant differences between 
complete data and imputed data for the risk factors primary site, NPVM, HCG, and 
LDH — although apart from LDH the differences were relatively small. More patients 
in the imputed than the complete data samples had good LDH values (80 and 67%, 
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respectively), fewer patients had intermediate LDH values (20 and 32%, 
respectively), and the proportion of patients in the poor category (1%) was similar 
(P < .001). As a consequence, a higher proportion of patients were allocated to the 
good prognosis group according to the IGCC classification in the imputed data 
sample, compared with complete data (59 and 55%, respectively). The number of 
patients allocated to each category varied little over the 10 imputed datasets for the 
variables primary site, NPVM, AFP, and HCG because these variables had a limited 
number of missing values.  
 
Table 2 IGCC risk factors and IGCC risk groups in the complete, imputed, 
and in all data 
 Patients, no. (% )   
 
IGCC risk factors 
Complete data Imputed data P-value1 Patients, all data,  
no. (% ) 
Sample size n = 3048 n = 2154  n = 5202 
Primary site   p<.001  
   Testis 2947 (97) 2117 (98)  5064 (97) 
   Mediastinum 101 (3) 37 (2)  138 (3) 
     
NPVM   p<.01  
   No 2808 (92) 1934 (90)  4742 (91) 
   Yes 240 (8) 220 (10)  460 (9) 
     
AFP2   p=.10  
   Good 2559 (84) 1802 (84)  4361 (84) 
   Intermediate 349 (11) 269 (12)  618 (12) 
   Poor 140 (5) 83 (4)  223 (4) 
     
HCG3   p<.001  
   Good 2660 (87) 1850 (86)  4510 (87) 
   Intermediate 238 (8) 144 (7)  382 (7) 
   Poor 150 (5) 160 (7)  310 (6) 
     
LDH4   p<.001  
   Good 2036 (67) 1816 (84)  3852 (74) 
   Intermediate 977 (32) 324 (15)  1301 (25) 
   Poor 35 (1) 14 (1)  49 (1) 
     
IGCC   p<.001  
   Good 1691 (55) 1392 (65)  3083 (59) 
   Intermediate 863 (28) 365 (17)  1228 (24) 
   Poor 494 (16) 398 (18)  892 (17) 
AFP, alpha-fetoprotein; HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; 
NPVM, nonpulmonary visceral metastases. 
1 P-value is based on average chi-square statistic over 10 datasets. 
2 AFP: good, <1000 ng/mL; intermediate, 1000–10000 ng/mL; poor, >10000 ng/mL. 
3 HCG: good, <5000 IU/L; intermediate, 5000–50000 IU/L; poor, >50000 IU/L. 
4 LDH: good, <1.5 × N; intermediate, 1.5–10 × N; poor, >10 × N (where N is the upper limit of 
normal) 
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By contrast, because a large number of values had to be imputed for LDH, the 
number of patients varied widely over LDH categories over the 10 imputed 
datasets: In the imputed data sample, minimum and maximum number of patients 
were 1683 and 1794, 348 and 457, and 10 and 19 for good, intermediate, and 
poor LDH, respectively. 
Five-year survival was significantly lower in the good, intermediate, and poor 
prognosis group in the imputed (87, 70, and 47%, respectively) data sample, 
compared with complete data (92, 80, and 50%, respectively) (Table 3). Because 
multiple imputation allowed for a more efficient use of the available data, the 
confidence intervals of the survival estimates in the all-data sample were smaller, 
compared with complete data. Discriminative ability was lower in the imputed data 
than in the complete data sample, with c-statistics of 0.68 and 0.73, respectively. 
This difference was not attributable to a difference in distribution of patients across 
the prognosis groups, because, given the distribution of IGCC prognosis groups in 
the imputed data, the expected c-statistic was 0.74. 
 
Table 3 Five-year survival by IGCC prognosis group and performance for 
complete, imputed, and all data 
 5-year survival, % (95% CI)  
 Good Intermediate Poor  Total 
Performance,  
c-statistic  
(95% CI) 
      
Complete data 92 (91-94) 80 (77-83) 50 (45-55) 82 (81-84) 0.73 (0.69-0.77) 
Imputed data 87 (85-89) 70 (66-75) 47 (42-52) 76 (74-78) 0.68 (0.64-0.73) 
Log-rank1 p<.025 p<.001 p<.025 p<.001  
All data 90 (89-91) 77 (74-79) 49 (46-52) 80 (79-81) 0.71 (0.67-0.74) 
1 Significance of log-rank for comparison of complete with imputed data based on average log-
rank statistic over 10 datasets 
 
The difference in survival between patients with and without missing values could in 
part be explained by differences in year of treatment. Survival increased over time, 
and the differences in year of treatment therefore resulted in differences in survival. 
With adjustment for year of treatment and IGCC prognosis group, the hazard ratio 
of missing IGCC (yes or no) decreased from 1.4 to 1.2 (P < .01). Further adjustment 
with other variables, such as region of treatment centre, did not further decrease the 
hazard ratio. 
Chapter 3 
72 
 
Figure 3 Hazard ratio for patients with nonseminomatous germ cell cancer by year 
of treatment. Dashed lines indicate the 95% confidence interval 
 
In Figure 3, the hazard ratio of year of treatment is plotted using a restricted cubic 
spline function with three knots against year of treatment for all patients 18. The 
relative hazard decreased strongly until 1985; thereafter, survival remained relatively 
constant. This relation also held when the complete data were analysed. No 
significant differences were seen according to region of treatment centre. The 
dependency on year of treatment limits the applicability of the obtained survival 
estimates for the good, intermediate, and poor prognosis group, especially after 
imputation, to more recently diagnosed patients. We therefore estimated 5-year 
survival for good, intermediate, and poor prognosis patients adjusted to the year 
1990 for all data and the complete data. For the all-data sample, the adjusted 5-year 
survival estimates for the good, intermediate, and poor prognosis groups were 93, 
85, and 62%, respectively. For complete data, 5-year survival estimates were very 
similar: 94, 86, and 62%, respectively.  
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When we selected only those patients treated after 1985, 5-year survival estimates 
for the good, intermediate, and poor prognosis groups for the all-data sample were 
93, 83, and 57%, respectively, and 95, 84, and 59% for patients with complete 
data. 
 
3.4 Discussion 
 
We found lower survival estimates for patients with nonseminomatous germ cell 
cancer after multiple imputation of the missing values in the IGCC database, 
compared with patients with complete data, especially for those in the intermediate 
prognosis group. The differences in survival between patients with and without 
missing values were, however, due mainly to differences in year of treatment, 
because year of treatment was related to both survival and missingness. 
In the analysis of the IGCC data, 2154 of 5202 patients (41%) were excluded 
because of one or more missing values. Missing values were due mainly to the 
absence of the tumour marker LDH, which occurred 1945 times. We used multiple 
imputation to create 10 complete datasets; by imputing the 2388 missing values in 
each dataset, 8382 real data values could be added. We used an extensive 
imputation model, including 18 variables significantly related to either the 
missingness or the value of LDH, to impute the missing values of the IGCC risk 
factors. We included the observed outcome (survival status and survival time), in 
line with the approach described by van Buuren et al 7.  
In general, using all available information results in multiple imputations that have 
minimal bias 13. The multiple imputation procedure assumes that values are missing 
at random: that is, that missing values are related only to observed variables and not 
to unobserved variables or the true unobserved value of the risk factor itself (which 
is missing not at random, MNAR). This seems a plausible assumption for the missing 
values of tumour marker LDH. LDH was established as an important risk factor only 
in the late 1980s, and was therefore not collected systematically by all centres. It 
remains possible, however, that missing values are related to unobserved values. 
Including many predictors in the multiple imputation model reduces the need to 
make special adjustments for missing-not-at-random problems 13. The multiple 
imputation of missing values leads to a more efficient use of the available data. If 
the imputation models specified and the assumption regarding the nonresponse 
mechanism are valid, multiple imputation leads to statistically better estimates. 
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Did the multiple imputation procedure also improve the clinical applicability of the 
survival estimates to currently diagnosed patients? In the IGCC database, survival 
increased over time, probably due to improvements in treatment regimens, but year 
of treatment was neither included in the IGCC classification nor otherwise 
accounted for. Therefore, the survival estimates of the IGCC classification are too 
low for currently diagnosed patients, even in the complete data sample of 3048 
patients. Because the probability of missingness was related to survival and year of 
treatment, MI led to the inclusion of even more historical patients and hence to a 
further underestimation of the survival of the IGCC classification. This 
underestimation limits the possibility to evaluate the results of currently conducted 
observational studies reporting on survival of patients with nonseminomatous germ 
cell cancer. For randomised controlled trials, this is not very problematic, because 
the effect of a treatment is directly compared with patients receiving another 
treatment; however, the results of nonrandomised phase II trials on dose-intensive 
or high-dose chemotherapy for poor prognosis patients might be interpreted too 
optimistically when compared with the 5-year survival estimate of 50% for poor-
prognosis patients in the IGCC classification 19-23. The same holds for outcome 
research, in which case series are reported to evaluate the treatment and outcome 
in one centre 24,25.  
To increase the clinical applicability, we adjusted survival for year of treatment, 
resulting in 5-year survival estimates of 93, 85, and 62% for good, intermediate, and 
poor prognosis patients, respectively. The adjusted estimates were similar for the 
complete and for all data and in line with survival estimates from more recent 
studies 24,25. This further demonstrates that, irrespective of the occurrence of missing 
values, year of treatment should have been taken into account in the development 
of the IGCC classification in order to obtain survival estimates applicable for 
currently treated patients. The validity of these adjusted estimates for currently 
diagnosed patients depends on the assumption that survival has not increased 
significantly over the last 15 years. Otherwise, survival estimates of the IGCC 
classification should be further updated. 
In conclusion, our results show that when missing values are related to time of 
treatment and survival has increased over time, multiple imputation of missing 
values does not result in survival estimates that are better applicable to currently 
diagnosed patients. The omission of important predictive variables in the 
development of a prognostic classification cannot be compensated by multiple 
imputation of missing values. 
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Abstract 
 
Background The International Germ Cell Consensus (IGCC) Classification 
distinguishes patients with nonseminomatous germ cell tumours (NSGCT) with a 
good, intermediate or poor prognosis, with a reported 5-year overall survival of 
92, 80 and 48%, respectively. Since the IGCC classification was based on patients 
treated between 1975 and 1990, we aimed to investigate whether survival has 
improved for more recently treated patients. 
Methods We did a systematic search of the literature and included studies on 
survival of patients with NSGCT, treated after 1989 and classified according to 
the IGCC classification. Survival estimates of selected studies were pooled using 
meta-analytic techniques. 
Results We included 10 papers, describing 1775 patients with NSGCT with good 
(n = 1087), intermediate (n = 232), or poor (n = 456) prognosis. Pooled 5-year 
survival estimates were 94, 83 and 71%, respectively.  
Conclusion Since the publication of the IGCC classification, there was a small 
increase in survival for good and intermediate prognosis patients, and a large 
increase in survival for patients with a poor prognosis. This increase is most likely 
due to both more effective treatment strategies and more experience in treating 
NSGCT patients.  
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4.1 Introduction 
 
Testicular germ cell tumours (seminomatous and nonseminomatous) are the most 
common cancers among young adult men. Since the 1970s the overall long term 
cure rate of patients with germ cell tumours has increased to over 80%, mainly 
due to the use of cisplatin-based chemotherapy that can cure advanced  
disease 1-4.  
Due to the high overall cure rate, interest has shifted to reducing treatment 
related toxicity for patients with a good prognosis 5. However, a small group of 
patients with a poor prognosis remains who might profit from alternative, more 
intensive treatment strategies 6-8.  
The coexistence of classifications differing in type, complexity and ability to 
separate good from poor prognosis, has complicated international collaboration 
in randomised trials and making comparison of nonrandomised studies 
impossible. Therefore, the International Germ Cell Consensus (IGCC) 
Classification was developed, based on individual patient data from previously 
conducted studies, which has now been widely adopted 9. The IGCC 
classification identifies good, intermediate, and poor prognosis groups using the 
following variables: primary site, presence of nonpulmonary visceral metastases 
(NPVM) and levels of the tumour markers alpha-fetoprotein (AFP), human 
chorionic gonadotrophin (HCG), and lactate dehydrogenase (LDH) (Table 1). 
According to the IGCC classification 56, 28 and 16% of patients with non-
seminomatous germ cell cancer were allocated to the good, intermediate and 
poor prognosis groups, with a 5-year overall survival of 92, 80 and 48%, 
respectively 9. The IGCC classification is currently the standard for selecting 
patients for randomised controlled trials (RCTs) 5,10,11 and for the analysis of 
observational studies, such as Phase I/II trials and hospital series. In observational 
studies, direct comparison with patients receiving standard treatment is not 
possible and, therefore, results are usually compared with the survival estimates 
reported by the IGCC classification.  
The IGCC classification is based on patients treated between 1975 and 1990. 
Survival might be better for more recently treated patients with non-
seminomatous germ cell tumours (NSGCT). There are some indications that 
indeed survival has improved. Sonneveld and colleagues reported a 10-year 
disease specific survival of 94, 87 and 66% for good, intermediate and poor 
prognosis patients treated between 1987 and 1996 3.  
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Table 1 The International Germ Cell Consensus 
(IGCC) Classification 9 
GOOD PROGNOSIS 
NONSEMINOMA 
Testis/retroperitoneal primary site 
And 
No nonpulmonary visceral metastases 
And 
AFP good and HCG good and LDH good 
 
56% of nonseminomas 
5 year PFS 89% 
5 year OS 92% 
INTERMEDIATE PROGNOSIS 
NONSEMINOMA 
Testis/retroperitoneal primary site 
And 
No nonpulmonary visceral metastases 
And 
AFP intermediate or HCG intermediate or LDH intermediate 
 
28% of nonseminomas 
5 year PFS 75% 
5 year OS 80% 
POOR PROGNOSIS 
NONSEMINOMA 
Mediastinal primary site 
Or 
Nonpulmonary visceral metastases 
Or 
AFP poor or HCG poor or LDH poor 
 
16% of nonseminomas 
5 year PFS 41% 
5 year OS 48% 
Tumour markers alpha-fetoprotein (AFP)/ human chorionic 
gonadotrophin (HCG)/lactate dehydrogenase (LDH): Good - 
AFP < 1000 ng/ml, HCG < 5000 iu/l, LDH < 1.5 x upper limit of 
normal; Intermediate - AFP 1000 – 10000 ng/ml, HCG 5000 - 
50000 ng/ml, LDH 1.5 - 10 x N; Poor - AFP > 10000 ng/ml, 
HCG > 50000 iu/l,  LDH > 10 x N 
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Germa-Llurch and colleagues reported a 3 year overall survival of 97, 89 and 72% 
for patients treated between 1994 and 2001 12.  
However, all relevant studies should be considered for a valid update of the 
survival estimates of the IGCC classification. We therefore conducted a meta-
analysis to update the survival estimates of the prognosis groups in the IGCC 
classification, using the most recent studies reporting on the survival of non-
seminomatous germ cell cancer patients. 
 
4.2 Material and Methods 
 
Literature search 
We conducted a systematic literature search of the PubMed database and the 
Cochrane Central library for the period January 1997 to December 2004. The 
terms used for the search were the text words “igcc” (OR “igccc”, “igcccg”, 
“IGCC”, “IGCCC”, “IGCCCG”), “germ cell” (OR “germ-cell”), “cancer” or “tumor” 
(OR “tumour “, “tumors”, tumours”) and the MeSH terms “neoplasms, germ cell 
and embryonal” and “testicular neoplasms”. The search was limited to “human”, 
and the English language. Furthermore, we used the ISI Web of Science to screen 
all papers referring to the original report by the IGCCCG and we screened all 
papers of the EORTC Genito-Urinary Tract Group on testicular cancer published 
since 1997. This resulted in 350 papers. 
Figure 1 shows the selection of papers for the meta-analysis. Of the 350 papers, 
284 papers reporting on children, other cancers, testicular cancer other than 
NSGCT (seminoma, relapse, residual mass, early disease), and the histology, 
biology, diagnosis, or treatment of testicular cancer, as well as review articles and 
double papers were excluded. The remaining 66 papers were retrieved for further 
evaluation. Forty-five papers were excluded because no survival estimates were 
given, patients were not classified according to the IGCC classification, 
overlapping datasets were described, no distinction between seminoma and non-
seminoma was made, less than 20 patients were included, or papers were 
published in a journal without an impact factor. When studies reported on the 
same patient population, the most recent study or the one with the longest follow 
up time was chosen. The 21 remaining papers mostly reported on previously 
published trials, in which patients were retrospectively allocated to the IGCC 
prognosis groups. Papers describing patients treated before 1989 (n = 11) were 
excluded due to possible overlap with the IGCCCG database resulting in 10 
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studies eligible for inclusion in the meta-analysis. One of these studies made no 
distinction in survival between seminomatous and nonseminomatous patients 5. 
Since this was the largest study on good prognosis patients, we requested the 
original data so that the study could be included in the meta-analysis.  
 
Data extraction and Analysis 
The following characteristics of the included 10 reports were extracted: treatment 
period, number of patients, median age, median follow up and overall or disease-
free survival. Furthermore, we noted the design of the study (Phase I, II or III trial, 
or hospital registry), IGCC prognosis group (good, intermediate, poor), number of 
patients per IGCC prognosis group and survival per IGCC prognosis group. 
Survival per prognosis group was obtained from tables or Kaplan - Meier plots. 
Since studies differed in years of follow up for which survival was given, survival 
estimates could not be obtained directly 13. We therefore pooled the survival 
curves of the 10 selected studies. For each curve the survival probability at each 
year of follow up was calculated by measuring the height of the curve at each 
year of follow up. Since information on censoring was not given in all studies, 
survival estimates could not be pooled using the exact number of patients at risk 
and the exact number of deaths per year of follow up. We therefore used a life 
table approach in which for each study the number of patients at risk and the 
number of deaths per year were based on the total number of patients in the 
study and the survival probability per year of follow up 13. Pooled survival 
estimates for each year were obtained by pooling the estimated number of 
patients at risk and the estimated number of deaths per year of follow up from 
each study. In two studies no survival curves were available 5,6. In these cases the 
reported 2-year overall survival was used to estimate the number of patients at 
risk and the number of events at one and two years of follow up. 
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Abstracts identified trough
Pubmed (n=36), Cochrane (n=18), EORTC
Genito-urinary tract group (n=12), and ISI Web of
Science (n=284)
(n=350)
Limits
time: 1/1/1997 - 31/12/2004
language: English
Papers retrieved for further evaluation (n=66)
Excluded (n=284),
reasons: children, other
cancers, no NSGCT
(seminoma, relapse, residual
mass, early disease), histology,
biology, treatment or
diagnosis germ cell cancer,
review articles, double papers
Papers considered for meta-analysis (n=21)
Excluded (n=45),
reasons: no survival estimates (n=2),
not classified according to the IGCC
classification (n=24), overlap in data
(n=9), seminoma and nonseminoma
not separated (n=2), < 20 patients
(n=6), journal with no impact factor
(n=2)
Papers selected for meta-analysis (n=10)
Excluded (n=11),
reason:
patients treated before 1989
 
Figure 1 Flow chart showing the selection process of publications for meta-
analysis. Note: NSGCT, nonseminomatous germ cell tumours 
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4.3 Results 
 
The 10 included studies reported data on 1775 patients with nonseminomatous 
germ cell cancer, treated between 1989 and 2001 (Table 2). The median age 
varied from 26 to 32 years, and median follow up time from 22 to 63 months. 
Eight studies reported overall survival as primary outcome, and two studies 
reported disease-specific survival 14,15. 
Table 3 shows study design, treatment regimen, number of patients per IGCC 
prognosis group and survival per IGCC prognosis group per study. Of the 1775 
patients available for analysis, 1087 (61%) were classified as good prognosis, 232 
(13%) as intermediate prognosis and 456 (26%) as poor prognosis patients. Three 
studies were based on hospital registries in which patients were treated with 
either standard-dose treatment cisplatin-etoposide-bleomycin (BEP), dose 
intensive regimens 12,16 or high-dose chemotherapy with stem cell support 15. 
Muramaki and colleagues describe the treatment results of 8 good prognosis, 24 
intermediate prognosis and 14 poor prognosis patients treated with either 
standard-dose chemotherapy (n = 29), or high-dose chemotherapy (n = 17) 15. No 
details were given on treatment received within the IGCC prognosis groups. Five-
year disease-specific survival was 88% for good prognosis, 77% for intermediate 
prognosis, and 71% for poor prognosis patients. Of the 178 patients described by 
Bhala and colleagues, 125 received standard-dose chemotherapy of whom 108 
were good prognosis, 9 intermediate prognosis and 8 poor prognosis patients. 
Forty-eight patients received dose intense alternating chemotherapy, POMB-ACE, 
of which 10 were good prognosis, 15 intermediate prognosis and 23 poor 
prognosis patients 16. Five-year survival was 95% for good prognosis patients, 
82% for intermediate prognosis, and 57% for poor prognosis patients. Germa-
Llurch and colleagues reported on 523 patients, of whom 485 patients were 
treated with standard-dose chemotherapy, and 38 of 96 poor prognosis patients 
with modified standard treatment BOMP-EPI 12,17. Three-year overall survival was 
97% for good prognosis, 89% for intermediate prognosis, and 72% for poor 
prognosis patients. Six Phase I or II trials evaluated new treatment regimens 
against standard treatment. 
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Table 2 Characteristics of 10 studies included in meta-analysis 
No. 
(Refs) 
 
Author 
(Year publication) 
Study 
period 
N 
Median 
age (yr) 
Median 
Follow up 
(months) 
Primary 
outcome 
1 15 
Muramaki et al 
(2004) 
1990 - 2001 46 31 63 5-yr DSS 
2 18 
Anthoney et al 
(2004) 
1995 - 1999 43 27 59 3-yr OS 
3 16 
Bhala et al 
(2004) 
1989 - 2001 178 29 22 5-yr OS 
4 14 
Schmoll et al 
(2003) 
1993 - 1999 182 29 47 5-yr DSS 
5 19 
Christian et al 
(2003) 
1989 - 2000 54 27 48 3-yr OS 
6 20 
Fizazi et al 
(2002) 
1993 - 1998 57 28 31 3-yr OS 
7 12 
Germa-Lluch et al 
(2002) 
1994 - 2001 523 26 33 3-yr OS 
8 5 
De Wit et al1 
(2001) 
1995 - 1998 630 32 25 2-yr OS 
9 21 
Decatris et al 
(2000) 
1994 - 1999 20 28 27 4-yr OS 
10 6 
Bokemeyer et al2 
(1998) 
1990 - 1995 42 - 31 2-yr OS 
       
  Total 1775    
OS, overall survival; DSS, disease specific survival 
N = Number of patients 
1 only nonseminoma included 
2  intermediate prognosis patients only, poor prognosis patients included in study 4 
 
Three Phase I/II trials evaluated the effect of dose intensive alternating 
chemotherapy (BOP + BEP), intensive induction chemotherapy (CBOP + BEP), or 
dose dense alternating chemotherapy (BOP + CISCA + BOMP + ACE) 18-20. These 
studies give survival estimates for 154 intermediate and poor prognosis patients 
ranging from 67 to 88%.  
Three studies evaluated the effect of high-dose chemotherapy with peripheral 
blood stem cell support 6,14,21. Survival for 202 poor prognosis patients was 66 
and 73%, respectively 14,21. The 42 intermediate prognosis patients receiving high-
dose chemotherapy had a 2-year overall survival of 89% 6. Only one study was a 
RCT 5. It showed the equivalence of 3 versus 4 cycles of bleomycin, etoposide 
and cisplatin for good prognosis patients, resulting in a 2-year overall survival of 
97%. 
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In Figure 2 survival estimates up to 7 years follow up are given for patients with 
good, intermediate, and poor prognosis separately. At 5 years follow up, pooled 
survival estimates were 94, 83 and 71% respectively for patients with good, 
intermediate, and poor prognosis.  
 
Table 3 Design, treatment, IGCC prognosis group, number of patients and 
survival per IGCC prognosis group of 10 included studies  
No. (Refs) 
 
Design Treatment IGCC 
Number 
of 
patients 
OS (95% CI) 
Good 8 88% 
Intermediate 24 77% 1 15 
Hospital 
registry 
BEP or HD-CT 
Poor 14 71% 
      
Intermediate 24 79% (57-91%) 
2 18 Phase II BOP+BEP 
Poor 19 84% (59-95%) 
      
Good 120 95% (91-100%) 
Intermediate 25 82% (65-98%) 3 16 
Hospital 
Registry 
BEP or 
POMB+ACE 
Poor 33 57% (36-79%) 
      
4 14 Phase I/II HD-VIP + PBSC Poor 182 73% 
      
5 19 Phase II CBOP+BEP Poor 54 88% (71-95%) 
      
Intermediate 19 83% (67-100%) 
6 20 Phase II 
BOP+CISCA + 
BOMP+ACE Poor 38 67% (53-84%) 
      
Good 329 97% (95-99%) 
Intermediate 98 89% (81-96%) 7 12 
Hospital 
registry 
BEP or BOMP+EPI 
Poor 96 72% (62-82%) 
      
8 5 Phase III BEP vs BEP + EP Good 630 97% 
      
9 21 Phase II 
BEP+HD-CEC+ 
PBSC 
Poor 20 66% 
      
10 6 Phase II HD-VIP + PBSC Intermediate 42 89% 
      
  Total Good 1087 94% 
   Intermediate 232 83% 
   Poor 456 71% 
Treatment details: BOP+BEP=bleomycin, vincristine, cisplatin + bleomycin, etoposide, cisplatin; 
BEP=bleomycin, etoposide, cisplatin; POMB+ACE=cisplatin, vincristine, methotrexate, bleomycin 
+ actinomycin D, cyclophosphamide, etoposide; HD-VIP + PBSC= high-dose cisplatin, etoposide, 
ifosfamide + peripheral blood stem cell support; CBOP+BEP= carboplatin, bleomycin, vincristine, 
cisplatin + bleomycin, etoposide, cisplatin; BOP+CISCA+BOMP+ACE= bleomycin, vincristine, 
cisplatin + cisplatin, cyclophosphamide, doxorubicin + cisplatin, vincristine, methorexate + 
bleomycin, etoposide, dactinomycin, cyclophosphamide; BOMP+EPI=bleomycin, vincristine, 
methotrexate, cisplatin + etoposide, ifosfamide, cisplatin; BEP + EP=bleomycin, etoposide, 
cisplatin + etoposide, cisplatin; HD-CEC = high-dose carboplatin, etoposide, cyclophosphamide 
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4.4 Discussion 
 
This meta-analysis demonstrated that survival of recently treated poor prognosis 
patients with nonseminomatous germ cell tumours was better than the survival 
reported by the IGCC classification. There was only a small increase in survival for 
patients with a good or intermediate prognosis. 
Based on a systematic review, we included 10 studies reporting on 1775 patients 
of which 1087 had a good prognosis, 232 intermediate and 456 poor. 
Five-year survival of poor prognosis patients has increased strongly (71 vs. 48%). 
This may partly be due to promising results obtained in Phase I/II trials with new 
treatments, although these results still need to be confirmed in RCTs. However, 
survival for poor prognosis patients may have increased over time irrespective of 
these more recent treatment regimens. 
First, because standard treatment improved when etoposide replaced vinblastine, 
after a RCT demonstrated that etoposide was more active and less toxic than 
vinblastine 3,22. Second, because research centres gained experience with the 
treatment of advanced testicular cancer 23. Furthermore improvements in second-
line treatment may also have contributed to an increase in survival, especially for 
poor prognosis patients 24. This is supported by two studies, excluded from the 
meta-analysis because of possible overlap with the IGCCG data. These two 
studies included patients who were treated with standard-dose chemotherapy and 
who were selected from hospital registries 3,8. Hinton and colleagues 8 reported 5-
year overall survival of 60% for poor prognosis patients treated with either 
standard-dose BEP or VIP, and Sonneveld and colleagues reported a 10-year 
disease-specific survival of 66% for poor prognosis patients treated with standard-
dose BEP 3,8. Furthermore, survival for poor prognosis patients treated after 1985 
was 59% in a retrospective analysis of the IGCCCG data 25.  
We found only a small increase in 5-year survival for good and intermediate 
prognosis patients compared to survival estimates reported by the IGCC 
classification (94 vs. 92% and 83 vs. 80%, respectively). While for good prognosis 
patients it has been established that 3 cycles and 4 cycles of BEP are equivalent 5, 
not much research has been done regarding intermediate prognosis patients, 
which explains the limited number of intermediate prognosis patients in this 
review compared to the original IGCC data (13 vs. 28%). Intermediate prognosis 
patients described in trials were initially selected for trials as having ‘advanced’ 
testicular cancer according to the Indiana classification, and were retrospectively 
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classified as intermediate prognosis according to the IGCC classification 26. One 
RCT by the EORTC compared BEP and VIP in intermediate prognosis patients and 
found no difference 27. However the use of different criteria than the IGCC 
classification to define intermediate prognosis patients limits the interpretation of 
the results of this RCT 9,28. Alternatives to standard-dose BEP could further 
improve survival for intermediate prognosis patients.  
Currently, intermediate prognosis patients are also being considered for high-dose 
chemotherapy with stem cell support in a RCT including both intermediate 
prognosis and poor prognosis patients 10. Furthermore the EORTC is currently 
conducting a large RCT comparing BEP with T-BEP (BEP + paclitaxel) for 
intermediate prognosis patients 29. 
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Figure 2 Pooled survival data for patients with nonseminomatous germ cell 
tumours treated after 1989, with either good, intermediate or poor prognosis 
according to the IGCC classification 
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Our study has some limitations. The survival estimates in our study might be 
overestimated due to publication bias. Trials showing good results for a certain 
treatment are more likely to be reported on. This effect could be even stronger in 
our study, since most data were published previously and later re-analysed 
according to the IGCC classification. This may have been done selectively, only 
considering those studies favouring an alternative treatment such as high-dose 
chemotherapy with stem cell support. 
Survival estimates might also have been overestimated due to selection bias 
within the studies. Patients participating in clinical trials are usually selected 
because of their relatively ‘good’ health (e.g. adequate renal function, adequate 
bone marrow function, no other major organ dysfunction) compared to patients 
not treated in a clinical trial. Since follow up differed between studies, we could 
not directly combine 5-year overall survival. Since not all studies provided 
information on number of patients at risk or 95% confidence intervals of survival 
estimates, the 95% confidence intervals of pooled estimates could not be 
provided. This illustrates the importance of reporting adequate information on 
survival, e.g., 95% confidence intervals and number of patients at risk. 
In studies describing poor prognosis patients all or almost all patients were 
treated with alternative treatment regimens, even in studies based on hospital 
registries 12,15,16. Since no RCTs have been published demonstrating the effect of 
these treatment regimens, it cannot fully be determined what causes the increase 
in survival for poor prognosis patients. 
Patients in the selected studies were mostly treated in clinical trials and centres 
specialized in the treatment of testicular cancer. This may limit the generalisability 
of the survival estimates to patients treated in other hospitals. However, Collette 
and colleagues concluded that poor prognosis patients should be treated in 
specialized treatment centres since larger centres with more experience had a 
better survival than smaller centres with less experience 23.  
We will have to wait for the completion of ongoing RCTs for poor prognosis 
patients to know what survival of patients receiving standard treatment is 
nowadays, and if new treatment regimens are really more effective. Currently two 
RCTs are investigating the effect of high-dose chemotherapy, one in Europe which 
is still including poor prognosis patients and one in the US for which accrual of 
patients has closed 10,11. Unfortunately, it may take years before the final results of 
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these RCTs are published, although insight into the 2-year survival would already 
be helpful. 
Meanwhile we will have to use the information available in the literature. Based 
on our meta-analysis we conclude that there was a large increase in survival for 
poor prognosis patients, while there was only a small increase in survival for good 
prognosis and intermediate prognosis patients. Although this could be explained 
by alternative treatment regimens investigated since the introduction of the IGCC 
classification, there is also evidence that survival increased over time irrespective 
of treatment received. We therefore recommend that results of Phase I/II trials for 
poor prognosis patients should no longer be compared with the survival estimates 
for poor prognosis patients reported by the IGCC classification as this may 
overestimate the effect of new treatment regimens. 
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Abstract 
 
Background In order to target intensive treatment strategies for poor prognosis 
patients with nonseminomatous germ cell cancer, those with the poorest 
prognosis should be identified. These patients might profit most from more 
intensive treatment strategies. For this purpose, a regression tree was previously 
developed on 332 patients. We aimed to evaluate the performance and structure 
of this tree.  
Patients and Methods The previously developed tree was applied to 456 patients 
with a poor prognosis as defined by the International Germ Cell Cancer 
Collaborative Group (IGCCCG). Next, we developed a new tree to evaluate 
whether a similar structure to the previous tree was found. We assessed the 
internal validity of the new tree, and compared the 2-year survival estimates of 
each subgroup together with the discriminative ability for both the previously 
developed and the new tree. Discriminative ability was measured by a 
concordance (c) statistic, which varies between 0.5 (no discrimination) and 1.0 
(perfect discrimination).  
Results The 2-year survival estimates in the IGCCCG data ranged from 33 to 63%. 
The ordering of the subgroups was different and discriminative ability was lower 
than originally found (c = 0.56 in the IGCCCG data vs. 0.63 originally). The new 
tree differed considerably from the original tree, and identified poor prognosis 
subgroups with 2-year survival estimates from 38 to 73%. Internal validation 
showed similar discriminative ability for the new tree and the original tree (c = 
0.59 vs. 0.56).  
Conclusion The previously developed tree showed poor validity with respect to 
discriminative ability and the stability of its structure. The performance of the new 
tree was also unsatisfactory. Given the low proportion of patients categorised as 
poor prognosis, it seems that the potential to identify further subgroups with the 
currently available patient characteristics is limited.  
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5.1 Introduction  
Patients with metastatic nonseminomatous germ cell tumours nowadays have a 
long term cure rate of >80%, because of the ability of cisplatin-based 
chemotherapy to cure advanced disease 1-4. Because of the high overall cure rate, 
interest has shifted to reducing treatment related toxicity for patients with a good 
prognosis 5. On the other hand poor prognosis patients should be considered for 
more intensive treatment strategies 6-8. The International Germ Cell Cancer 
Collaborative Group (IGCCCG) developed the International Germ Cell Consensus 
(IGCC) classification to distinguish patients according to prognosis 9. The IGCC 
classification is currently widely applied. It distinguishes patients with good, 
intermediate and poor prognosis. The poor prognosis group consists of ~15% of 
all patients and is characterised by the presence of mediastinal primary site, non-
pulmonary visceral metastases or poor tumour marker levels. Long term survival 
following standard treatment may be ~50% 9. To further improve the long term 
survival in poor prognosis patients, those who are most likely to fail standard 
treatment should be identified. These patients are most likely to profit from novel 
chemotherapy approaches, such as dose intensification and high-dose 
chemotherapy with stem cell support 10. Dose intensification with either sequential 
or alternating non-cross-resistant chemotherapy has shown promising results in 
nonrandomised trials 11, but this has not been confirmed in randomised clinical 
trials  10,11.  
Studies conducted by the Memorial Sloan Kettering Cancer Center  12,13 and the 
German Testicular Cancer Group 7,14 showed beneficial effects for high-dose 
chemotherapy with stem cell support and high-dose chemotherapy, respectively. 
However these results were based on nonrandomised trials and comparisons with 
historical controls. To confirm these results, two randomised, multicentre trials are 
currently being conducted in the USA and Europe 15. Furthermore, the 
identification of subgroups among poor prognosis patients would allow for a 
more accurate estimate of the individual patients' chances of survival, and increase 
the comparability of results from clinical trials 16. 
Kollmannsberger et al 16 used tree modelling as an explorative method to identify 
important risk factors within a group of poor prognosis patients, as defined by the 
IGCC classification, and to find subsets of patients differing in prognosis. They 
developed a regression tree based on data of 332 poor prognosis patients as 
defined by the IGCC classification (Kollmannsberger tree). The risk factors visceral 
metastases, primary site and abdominal mass were used. 
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Figure 1 Trees for poor prognosis patients with nonseminomatous germ cell 
cancer with 2-year survival, 95% confidence interval and number of patients (n) 
(A) Kollmannsberger tree applied to the Kollmannsberger data (B) 
Kollmannsberger tree applied to the International Germ Cell Cancer Collaborative 
Group (IGCCCG) poor prognosis data (C) International Germ Cell Consensus 
(IGCC) tree applied to the IGCCCG poor prognosis data 
 
This resulted in a tree with five poor prognosis subgroups (Figure 1a). The 
subgroups differed in 2-year survival, ranging from 49 to 84% 16. 
Tree models are attractive ways to identify subsets of patients because they are 
easy to apply and interpret. They have few restrictions, which makes them suitable 
for finding interactions between risk factors 17-20. Furthermore, trees have more 
resemblance with the way clinicians make decisions than linear models 17. On the 
other hand, this flexibility makes trees ‘data hungry’. Use of relatively small 
datasets will lead to unstable tree models, and optimism in the performance of the 
model due to overfitting 17,21,22. 
Kollmannsberger et al 16 recognise these problems and the limitations of their tree. 
Some subgroups only had a small number of patients, and their identification may 
be the result of pure chance. Such subgroups may not be present when new data 
are considered. Furthermore, survival estimates of small groups are often 
unreliable. This was illustrated by the group of patients with visceral metastases 
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and primary site testis, in which patients with an abdominal mass had a higher 2-
year survival (72%; 95% confidence interval (CI) 64–80%) than patients without 
(52%; 95% CI 27–77%). Kollmannsberger et al 16 therefore propose that further 
confirmatory studies in other poor prognosis patients cohorts are needed, before 
the tree can be used in practice.  
The aim of the present study was to evaluate the validity of the Kollmannsberger 
tree. We consider two aspects of validity: performance and the structure of the 
tree model. We evaluated the performance of the Kollmannsberger tree by 
applying the tree to the poor prognosis patients in the IGCCCG database 9. 
Furthermore, we developed a new tree for the poor prognosis patients in the 
IGCCCG database to study whether its structure, that is the selection and 
hierarchy of risk factors, was similar to the Kollmannsberger tree.   
 
5.2 Patients and Methods 
Patients 
The Kollmansberger tree was based on data from 332 patients with metastatic 
nonseminomatous germ cell tumours, from prospective clinical trials conducted 
between 1984 and 1997 23,24. All patients were treated for poor prognosis disease, 
as defined by the IGCC classification 9, with either cisplatin–etoposide–ifosfamide 
(PEI) or cisplatin–etoposide–bleocymin (PEB).  
To validate the Kollmannsberger tree, we used the 495 poor prognosis patients 
with nonseminomatous germ cell cancer from the IGCCCG database, which 
consists of 5202 adult male patients. Poor prognosis was defined by the presence 
of any of the poor risk factors mediastinal primary site, (nonpulmonary) visceral 
metastases, alpha-fetoprotein (AFP) poor (>10000 ng/ml), human chorionic 
gonadotrophin (HCG) poor (>10000 ng/ml) and lactate dehydrogenase (LDH) 
poor (>10 times the upper limit of normal) 9. 
Patients were treated between 1975 and 1990 with cisplatin-based 
chemotherapy. Data were collected on age, primary site, date of diagnosis, levels 
of serum AFP, HCG and LDH, nodal disease in the abdomen, mediastinum, neck, 
lung metastases, spread to other visceral sites such as liver, bone and brain, and 
on treatment details such as previous therapy 9. Data for 39 patients were 
excluded because of missing values on the risk factors age, and lung, liver, bone 
and brain metastases. The endpoint was overall survival, calculated from the 
beginning of chemotherapy.  
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Statistical analyses 
We assessed the performance of the Kollmannsberger tree by applying it to the 
456 poor prognosis patients in the IGCCCG database. Two-year overall survival 
was calculated using the Kaplan–Meier method.  
Furthermore, a new tree was developed in the poor prognosis patients in the 
IGCCCG database and the result compared with the Kollmannsberger tree to 
evaluate its structure, that is the selection and hierarchy of the risk factors. We will 
refer to this new tree as the IGCC tree. For the development of this tree we used 
the same candidate risk factors and coding as Kollmannsberger et al 16. We first 
determined the risk factor that best split the data into two subgroups, leading to 
the largest decrease in prediction error. Splitting continued until a group reached a 
minimum size of five, or until no further improvement in discrimination could be 
made, based on the loss in exponential log-likelihood. The full tree, which might 
be too complex and overfit, was pruned using 10-fold crossvalidation. All trees 
within one standard error of the lowest crossvalidated prediction error were 
considered as equivalent. A final tree was selected from these equivalent 
trees19,20,25.  
Modelling was performed with S-plus version 2000 using the RPART library, which 
contains a recursive partitioning method for survival data. The RPART library 
(rpart2.zip) and manual (rpart2doc.zip) can be found at 
http://www.stats.ox.ac.uk/pub/SWin. 
For comparison we fitted a Cox regression model using the same risk factors in 
the poor prognosis patients in the IGCCCG database. All risk factors were entered 
in the model and the final model was obtained with a backward stepwise 
selection procedure using a P-value of 0.05.  
 
Predictive performance 
We determined the discriminative ability, to indicate the predictive performance 
of the Kollmannsberger tree, the IGCC tree and the Cox regression model. The 
discriminative ability indicates how well a model can distinguish between patients 
with different survival expectations and was measured by a concordance statistic 
(c-statistic). For binary outcomes, the c-statistic is identical to the area under the 
ROC curve 26,27. The c-statistic for survival data estimates the probability that for a 
randomly chosen pair of patients, the one having the higher predicted survival is 
the one who survives longer 26. The c-statistic varies between 0.5 and 1.0 for 
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sensible models. A predictive model with a c of 0.5 has no predictive value, while 
a model with a c of 1.0 discriminates perfectly between patients differing in 
survival. C-statistics were computed for the Kollmannsberger tree, when applied 
to the Kollmannsberger patients or the IGCCCG patients, for the IGCC tree and 
for the Cox regression model. The steps taken in the development of the IGCC 
tree were internally validated by taking 100 random bootstrap samples. The 
development process of the tree was repeated for every bootstrap sample and the 
resulting tree tested on the original sample, to estimate and correct for the 
optimism in discriminative ability 28,29. The original sample hence served as the 
test sample for models developed in the bootstrap samples. The Cox regression 
model was validated according to the same procedure. The standard error of the 
corrected c-statistic was taken from the empirical distribution of the c-statistics in 
the test sample. This standard error was used to calculate the 95% CI of the 
optimism-corrected c-statistic.  
 
5.3 Results 
 
Patient characteristics are given in Table 1, both for the 456 poor prognosis 
patients of the IGCCCG study and the 332 patients of the Kollmannsberger study. 
More than half of the IGCCCG poor prognosis patients had primary site testis 
(67%), lung metastases (62%) or abdominal masses (70%). Sixty-three per cent of 
the patients had poor AFP, HCG or LDH levels. The presence of liver metastases 
was common (34%). The distribution of the patient characteristics age, lung 
metastases, visceral metastases, abdominal masses, number of metastatic sites and 
tumour markers, combined as well as separate, and follow up time was largely 
similar for the IGCCCG and the Kollmannsberger studies. Disease progression 
occurred in 252 of the IGCCCG poor prognosis patients. Of the 223 patients who 
died, 213 were categorised as disease-related. 
The corresponding 2-year survival was 56% (95% CI 52–61%) for the IGCCCG 
poor prognosis patients. This differs from the Kollmannsberger data, where 2-year 
survival was 72% (95% CI 67–77%).  
The Kollmannsberger tree was applied to the poor prognosis patients in the 
IGCCCG database, as presented in Figure 1b. The split according to the presence 
of visceral metastases resulted in two subgroups with only slightly different 2-year 
survival (59 and 53%).  
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Table 1 Patient characteristics, Kolmannsberger and IGCCCG poor 
prognosis data  
 Kolmannsberger IGCCCG 
Patient characteristics Number of patients (%) Number of patients (%) 
Age     
     Median 28  27  
     Range 15-62  14-67  
Primary site     
     Mediastinum 72 (22) 98 (22) 
     Retroperitoneal 31 (9) 51 (11) 
     Testis 229 (69) 307 (67) 
Lung metastases 247 (74) 283 (62) 
Visceral metastases 205 (62) 232 (51) 
     Liver 131 (39) 153 (34) 
     Bone 35 (11) 31 (7) 
     CNS/Brain 33 (10) 36 (8) 
     Other 6 (2) 12 (3) 
Abdominal mass 205 (62) 318 (70) 
Abdominal mass >10 cm 120 (36) 179 (39) 
Marker combined     
     Good 18 (6) 37 (8) 
     Intermediate 104 (31) 133 (29) 
     Poor 210 (63) 286 (63) 
AFP     
     Good 189 (57) 247 (54) 
     Intermediate 68 (20) 80 (18) 
     Poor 72 (22) 129 (28) 
     Missing 3 (1)   
HCG     
     Good 180 (54) 260 (57) 
     Intermediate 34 (10) 54 (12) 
     Poor 117 (35) 142 (31) 
     Missing 1 (1)   
LDH     
    Good 79 (24) 104 (23) 
    Intermediate 197 (59) 318 (70) 
    Poor 38 (12) 34 (7) 
    Missing  18 (5)   
Number of metastatic sites     
    Median 2  2  
    Range 0-5  1-5  
Number of patients  ≥ 3 metastatic sites 159 (48) 216 (47) 
Status at last follow up     
  CR/PR 215 (65) 204 (45) 
  AWD 14 (5) 29 (6) 
  Dead by disease 95 (28) 213 (47) 
  Dead other cause 8 (2) 10 (2) 
Follow up in months     
  Median 23+  23  
  Range 0-99  1-170  
Time of treatment 1984-1997 1975-1990 
Total number of patients 332  456  
Good/intermediate/poor tumour markers according to the IGCC classification.  
IGCCCG, International Germ Cell Cancer Collaborative Group; AFP, alfa-fetoprotein; HCG, 
human chorionic gonadotrophin; LDH, lactate dehydrogenase; CR, complete remission; PR, 
partial remission; AWD, alive with disease; IGCC, International Germ Cell Consensus 
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Both branches were split further according to primary site, resulting in two final 
groups in the no visceral metastases branch, with 2-year survival of 63 and 50%, 
and in the visceral metastases branch in one final group with 2-year survival of 
33% and one further subgroup with 2-year survival of 56%; the last final groups 
from this branch were defined by the presence of abdominal mass, with similar 2-
year survival (56 and 53%). As can be seen by comparing  figure 1b and 1a, 
respectively, the 2-year survival estimates for the five final groups identified in the 
poor prognosis patients in the IGCCCG database by the Kollmannsberger tree 
were less extreme than in the original Kollmannsberger tree. This was reflected by 
the lower discriminative ability in the IGCCCG poor prognosis data (c = 0.56; 
95% CI 0.49–0.64) compared with the original data (c = 0.63; 95% CI 0.56–0.70).  
The newly developed IGCC tree is presented in Figure 1c. Trees with two to six 
groups gave equivalent performance based on the loss in exponantial log-
likelihood. However, a tree with five final groups was chosen for fair comparability 
with the Kollmannsberger tree. The 2-year survival ranged from 38 to 73%. The 
principal determinant of survival was the total number of metastases, where three 
or fewer metastases resulted in a subgroup with a 2-year survival of 61% and the 
presence of more than three metastases in a final group with a 2-year survival of 
38%. The next split was made by primary site, resulting in a subgroup of patients 
with testis as primary site and a 2-year survival of 64% and a final group of 
patients with mediastinal primary site and a 2-year survival of 49%. A further 
distinction was made by the size of an abdominal mass, resulting in a 2-year 
survival of 73% for patients with a mass ≤10 cm, and 56% for a mass >10 cm. 
Finally, the presence of lung metastases resulted in two final groups with a 2-year 
survival of 67% for patients without lung metastases and 42% for patients with 
lung metastases.  
Thus, both the Kollmannsberger tree and the new IGCC tree selected primary site 
and abdominal mass as important risk factors, although the Kollmannsberger tree 
selected the presence of abdominal mass rather than size. Furthermore, the 
presence of lung metastases was used in the IGCC tree, but not in the 
Kollmannsberger tree. The apparent discriminative ability of the new IGCC tree 
was similar to the discriminative ability of the Kollmannsberger tree, with a c-
statistic of 0.63 (95% CI 0.62–0.72). Internal validation revealed an optimism in c-
statistic of 0.04, leading to an optimism-corrected estimate of c = 0.59 (95% CI 
0.54–0.63) for the new IGCC tree when applied to future patients similar to those 
included in the IGCCCG database.  
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The Cox regression model selected the risk factors primary site, presence of 
abdominal mass, size of abdominal mass, total number of metastases, AFP and 
tumour markers combined. The discriminative ability of the Cox regression model 
was slightly higher, with a c-statistic of 0.64, but decreased to 0.61 after correction 
for optimism.  
 
5.4 Discussion 
The previously developed tree to identify subgroups among poor prognosis 
patients with nonseminomatous germ cell cancer showed poor validity in the 
poor prognosis patients in the IGCCCG database. First, the discriminative ability 
of the Kollmannsberger tree was substantially lower (c = 0.56) than in the original 
data (c = 0.63). Secondly, a new tree was developed in the poor prognosis 
patients in the IGCCCG database, which used the number of metastases, primary 
site, size of abdominal mass and the presence of lung metastases to identify 
subgroups, whereas the Kollmannsberger tree used the presence of visceral 
metastases, primary site and abdominal mass as risk factors. The discriminative 
ability of the new tree, c = 0.59 at internal validation, was similar to the 
Kollmannsberger tree (c = 0.56).  
In our case, the selected risk factors were rather similar in the trees developed 
with the Kollmannsberger data and the IGCCCG poor prognosis data (presence 
versus size of abdominal mass and presence versus number of metastases). The 
structure of the trees, however, was very different. Since primary site was an 
important risk factor in patients with and without visceral metastases in the 
Kollmannsberger tree, both risk factors can be interpreted statistically as main 
effects. In the IGCC tree, primary site occurred only once, and no main effects 
were present except for the number of metastases. Furthermore, the trees fitted in 
the bootstrap samples varied in size, the smallest tree having only two groups and 
the largest tree 20. A tree size of four was most prevalent (14% of cases). The 
flexibility in structure and tree size led to optimism in the performance of the tree 
developed on the IGCCCG poor prognosis data, where the c-statistic was 
expected to decrease from 0.63 to 0.59 according to a bootstrap validation 
technique. Hence, the flexibility of tree modelling may have more cons than pros 
in small datasets, that is datasets with relatively few deaths. Larger datasets are 
required for reliable application of tree modelling.  
The discriminative ability of a Cox regression model was slightly higher than the 
regression tree models with a c-statistic of 0.61 at internal validation. A Cox 
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regression model was not available for the Kollmannsberger data. Should such a 
model be applied to the Kollmannsberger data, the selection and the number of 
risk factors might differ. However, the structure is likely to be similar for a given 
selection of risk factors, since we usually fit main effects only in a regression 
model. In relatively small datasets, this may be the most sensible, since we have 
insufficient statistical power to identify important interaction terms 30.  
To assess whether the Kollmannsberger tree can be generalised to other patients, 
we applied it to poor prognosis patients from the IGCCCG dataset. The 
comparison of the Kollmannsberger and the IGCC tree was, however, limited by 
the differences in the two datasets. Although the distribution of risk factors in the 
Kollmannsberger and IGCCCG poor prognosis data was largely similar, there was 
a difference in 2-year survival (72 and 56%, respectively). These differences may 
reflect the different time periods in which the data were collected 
(Kollmannsberger 1984–1997, IGCCCG 1975–1990). Owing to improved 
treatment strategies, survival has increased over time 4,31. Patients in the 
Kollmannsberger study were treated with regimens of either PEB or PEI. Although 
all poor prognosis patients in the IGCCCG database were treated with cisplatin-
based chemotherapy, patients from the late 1970s and early 1980s were probably 
treated with the cisplatin–vinblastine–bleocymin regimen rather than PEB. The 
differences between the populations suggest that a more recent population of 
poor prognosis patients might be more suitable to assess the generalisability of 
the Kollmannsberger tree. Ideally, to assess the differences between the 
Kollmannsberger and the IGCCCG poor prognosis data and to make an honest 
comparison between both trees, the new IGCC tree should be applied to the 
Kollmannsberger data.  
Better performance might be achieved by adding stronger risk factors that have 
not been used before in the classification of patients with germ cell cancer. 
Besides pre-treatment characteristics, the rate of tumour marker decline during the 
first two cycles of chemotherapy has been identified as an important risk factor. 
Rate of tumour marker decline predicted outcome in 189 patients, independent 
of risk status as defined by the IGCC classification, especially in poor prognosis 
patients 32. Similar results were found in 139 poor prognosis patients in a 
previously conducted study 33. These results will be validated with data from a 
multicentre, randomised clinical trial 32. Furthermore, promising research is being 
carried out on the prognostic value of molecular and genetic markers. Knowledge 
on the role of such markers will not only allow for a better understanding of the 
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development and progression of testicular gem cell cancer, but may also lead to a 
more refined assessment of prognosis and better management of germ cell 
tumours 34,35. 
In conclusion, survival of IGCC poor risk patients in the present day may have 
improved compared with the historical IGCCCG data. This justifies the 
investigation of poorer risk subgroups, although the difficulties in evaluating new 
treatment approaches through randomised trials in these small groups must be 
acknowledged. The performance of the current regression trees was 
unsatisfactory. The currently available risk factors are not strong enough to clearly 
identify subgroups among poor prognosis patients with nonseminomatous germ 
cell cancer, who comprise a small subgroup (~15%) of metastatic germ cell 
tumour patients. A new model might incorporate molecular and genetic markers 
in addition to the risk factors currently incorporated in the IGCC classification. We 
suggest the use of Cox regression for the construction of such a new model, 
rather than tree modelling. This method is proven to be more stable and gives less 
optimistic results, especially in smaller datasets. Tree modelling can give insight 
into possible interactions between risk factors provided sufficient data is available, 
but should be restricted to exploratory analyses.  
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Abstract 
Introduction Classification systems may be useful to direct more intensive 
treatment to cancer patients with a relatively poor prognosis. The definition of 
‘poor prognosis’ often lacks a formal basis. We propose a decision analytic 
approach to weigh benefits and harms explicitly to define the treatment threshold 
for more intensive treatment. This approach is illustrated by a case study in 
advanced testicular cancer, where patients with a high risk of mortality under 
standard treatment may be eligible for high-dose chemotherapy with stem cell 
support. 
Materials and methods We used published literature to estimate the benefit and 
harm of high-dose chemotherapy (HD-CT) versus standard-dose chemotherapy 
(SD-CT) for patients with advanced nonseminomatous germ cell cancer. Benefit 
and harm were defined as the reduction and increase in absolute risk of mortality 
due to HD-CT respectively. Harm included early and late treatment related death, 
and treatment related morbidity (weighted by ‘utility’). 
Results We considered a conservative and an optimistic benefit of 30 and 40% 
risk reduction respectively. We estimated the excess treatment related mortality at 
2%. When treatment related morbidity was taken into account, the harm of HD-
CT increased to 5%. With a relative benefit of 30% and harm of 2 or 5%, HD-CT 
might be beneficial for patients with over 7 or 17% risk of cancer specific 
mortality with SD chemotherapy, while with a relative benefit of 40% HD-CT was 
beneficial over 5 and 12.5% risk respectively. 
Conclusion Benefit and harm can be used to define ‘poor prognosis’ explicitly for 
nonseminomatous germ cell cancer patients who are considered for high-dose 
chemotherapy. This approach can readily be adapted to new results and 
extended to other cancers to define candidates for more intensive treatments.  
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6.1 Introduction  
The prognosis of a cancer patient is of key importance in the choice of more or 
less intensive treatment. Prognostic estimates can be based on extent of disease, 
as for example reflected in TNM stage, on age and comorbidity, and on specific 
characteristics, such as values of tumour markers 1. Prognostic classifications can 
facilitate decision-making by grouping patients with a similar prognosis. Poor 
prognosis patients may be considered candidates for more intensive treatment 
strategies, while good prognosis patients may be treated with less burdensome 
interventions, for example by less toxic chemotherapy regimens 2,3. Prognostic 
classifications use estimated survival to identify poor prognosis patients eligible 
for alternative treatments. However this approach only implicitly takes the 
possible side effects of an alternative treatment into account. Ideally both the 
expected gain in survival (benefit) and the toxic side effects or burden due to 
treatment (harm) are considered 4. 
We propose a decision analytic approach in which both benefit and harm of an 
alternative treatment are explicitly specified and weighed to determine which 
patients could profit from this alternative treatment strategy. 
The decision analytic approach is illustrated in Figure 1. Benefit of treatment is the 
reduction in absolute risk of cancer mortality due to treatment. Benefit increases 
linearly with risk of cancer mortality assuming that patients with the highest risk 
have most to gain. Harm is the increase in absolute risk of treatment mortality 
(e.g. related to toxicity) due to treatment. The level of harm is the same for all 
patients, assuming that for example the toxicity of treatment is independent of 
prognosis. Patients are candidates for more intensive treatment when their risk of 
cancer mortality is above the threshold, i.e. when benefit is higher than harm. 
As an example we consider high-dose chemotherapy (HD-CT) as first line 
treatment to improve survival of patients with nonseminomatous germ cell 
cancer. Several nonrandomised trials reported a higher survival for poor prognosis 
patients treated with HD-CT as first line treatment (including etoposide, 
ifosfamide, cisplatin) with autologous stem cell support, compared to standard-
dose chemotherapy (SD-CT) (including bleomycin, etoposide, cisplatin) 5-7. 
Furthermore, HD-CT is currently considered in two RCTs by the European 
Organisation for Research and Treatment of Cancer (EORTC) and by the US 
intergroup 8,9. However, HD-CT is related to a higher toxicity, both during 
treatment (e.g. granulocytopenia, anaemia, nausea/vomiting, diarrhoea), shortly 
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after treatment (e.g. pulmonary toxicity) and long after treatment (e.g. leukaemia, 
cardiovascular disease) 5,10.  
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Figure 1 Benefit and harm of treatment, expressed on the same scale. Benefit of 
treatment (reduction in absolute risk) increases with risk, while harm of treatment 
(excess absolute risk, e.g. due to toxicity of treatment) is constant. Net benefit 
occurs only when risk is above the threshold 4  
 
So far studies on HD-CT focus on patients with a poor prognosis according to the 
International Germ Cell Consensus (IGCC) Classification 11. The IGCC 
classification combined 5 risk factors to define a good, intermediate and poor 
prognosis group based on survival. Good prognosis patients are considered 
eligible for less intensive treatment reduce treatment related toxicity 12, 
intermediate prognosis patients usually receive standard treatment, and poor 
prognosis patients are considered candidates for more intensive treatment.  
The aim of this study is to use a decision-analytic approach to determine how high 
the risk of patients with nonseminomatous germ cell cancer should be in order to 
profit from high-dose chemotherapy with stem cell support. Estimates of benefit 
and harm of high-dose chemotherapy were based on currently available literature. 
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6.2 Materials and methods 
Of the different high-dose chemotherapy (HD-CT) treatment strategies currently 
investigated we considered the benefit and harm of the HD-CT approach by the 
German testicular cancer group 5. 
We considered benefit and harm till 10 years after treatment, since longer term 
evidence is scarce. 
 
Benefit 
Benefit is based on the reduction in relative risk due to HD-CT compared to 
standard chemotherapy. 
 
Benefit is expressed as: 
 
(1) 1 – (R C-MORT HD-CT/R C-MORT SD-CT) 
 
where RC-MORT HD-CT is the risk of cancer mortality with HD-CT and RC-MORT SD-CT the 
risk of cancer mortality with standard chemotherapy. This relative risk reduction 
translates into a decrease in absolute risk of cancer mortality at the patient level. 
When HD-CT results in a relative risk reduction of 25%, absolute risk decreases 
10% for patients with a risk of cancer mortality of 40% (0.25 x 40%), whereas for 
a patient with a risk of cancer mortality of 80% the absolute risk reduction is 20% 
(0.25 x 80%).  
Although benefit should preferably be based on results of RCTs it will take several 
more years before the results of RCTs comparing HD-CT to SD-CT become 
available. Therefore we estimated risk of cancer mortality due to HD-CT and SD-
CT from three observational studies; two on patients treated with SD-CT and one 
on patients treated with HD-CT 5,13,14. These observational studies reported on 
either 5-year or 10-year survival. To estimate benefit we need the risk of cancer 
mortality due to SD-CT and HC-CT 10 years after treatment. 
We therefore translated survival into risk of cancer mortality at 10 years.  
Firstly, overall survival (SOVERALL) in each study was translated to risk of overall 
mortality due to treatment (ROVERALL).  
 
(2) ROVERALL = 1 – SOVERALL  
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From the overall risk of mortality we determine the risk of cancer mortality (RC-
MORT) by subtracting risk of treatment mortality (RT-MORT). We ignore mortality due 
to other causes since testicular cancer patients are relatively young. 
 
 (3) RC-MORT  = ROVERALL  – RT-MORT  
 
Finally, we assumed that the relative increase in risk between 5 years and 10 
years after treatment was 20% and increased the risk of cancer mortality 
accordingly 11. The resulting estimates of cancer mortality 10 years after treatment 
of the two studies on SD-CT were combined in a weighted average by study size. 
 
Harm 
Harm is the excess risk of mortality due to HD-CT and is assumed to remain 
comparatively constant. We considered the excess risk of mortality and morbidity 
using published literature. 
Treatment mortality consisted of early treatment mortality (<6 months) and late 
treatment mortality (>6 months). We based late treatment mortality (R LATE T-MORT) 
on the incidence and fatality of long term complications. Fatality was assumed to 
be identical for patients treated with HD-CT or SD-CT once a complication 
occurred, although no information was available on similarity of fatality between 
patients treated with either SD-CT or HD-CT. 
The excess risk of late treatment mortality is the difference in incidence multiplied 
by the estimated fatality:  
 
(4) ∆ R LATE T-MORT = (incidence HD-CT – incidenceSD-CT) x fatality. 
 
Late treatment morbidity (R LATE T-MORB) was made comparable to mortality by 
weighing complications by their utility value. Utility (U) is a measure of health 
related quality of life, ranging from 0 to 1, where a weight of 1 corresponds to 
perfect health and a weight of 0 corresponds to a health state judged equivalent 
to death 15. By expressing long term complications in utilities, treatment related 
morbidity could be directly compared with treatment related mortality.  
We estimated late treatment morbidity for SD-CT and HD-CT by combining the 
incidence and utilities of long term complications up to 10 years after treatment. 
We obtained utilities for long term complications from available literature 15.  
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The risk of excess late treatment morbidity for surviving patients is: 
 
(5) ∆R LATE T-MORB = (incidence HD-CT – incidence SD-CT) x (1-U) x (1-fatality). 
 
Sensitivity analysis 
We considered a conservative and an optimistic scenario for benefit, since only 
observational data were available. Further, a constant relative risk reduction 
assumes a linear relationship between benefit and risk, where benefit is absent for 
patients with no risk, and maximal for patients with 100% risk of cancer mortality. 
Alternatively we considered a nonlinear relationship between benefit and risk, in 
which benefit is absent for patients with no risk or 100% risk and maximal for 
patients with a 50% risk of cancer mortality. We determined the threshold for 
such a parabolic relation between benefit and risk, for both the optimistic and 
conservative scenario. Finally, we calculated treatment thresholds for more 
intensive therapy when benefit and harm were varied over wide ranges. 
 
6.3 Results 
Benefit 
The three observational studies on which our estimate of benefit of HD-CT was 
based are presented in Table 1. Sonneveld et al reported 10-year disease specific 
survival of 66% for 22 patients treated with SD-CT in their hospital between 1987 
and 1996 16. A RCT comparing standard-dose bleomycin-etoposide-cisplatin (BEP) 
with standard-dose etoposide-ifosfamide-cisplatin (VIP) reported a 5-year overall 
survival of 60% for 181 poor prognosis patients 13. Schmoll et al reported 5-year 
survival of 73% for 182 patients treated with HD-CT between 1993 and 1999 5. 
Combined, the 203 patients treated with SD-CT had an estimated 10-year risk of 
cancer mortality of 43%, which was substantially higher than that for the 182 
patients treated with HD-CT chemotherapy (10-year risk of cancer mortality 28%). 
The pooled estimate of benefit is 35% (RRR=1 – (28%/43%)). For our 
conservative scenario we assume a benefit of 30% and for our optimistic scenario 
a benefit of 40%. 
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Table 1 Survival and early treatment related death in nonseminomatous germ 
cell cancer patients treated with high-dose (HD) or standard-dose (SD) 
chemotherapy 
Reference Tx Year Tx N SOVERALL F-up ROV-MORT 
 
Early 
toxic 
death2 
RC-MORT RC-MORT 10 yrs 
Hinton et al 
13 
SD 1987-1992 181 60% 5 40% 3% 37% 44% 
Sonneveld 
et al 16 
SD 1987-1996 22 66%1 10 34% NA 31% 31% 
Schmoll et 
al 5 
HD 1993-1999 182 73%1 5 27% 4% 23% 28% 
Tx = treatment 
SOVERALL = Overall survival at year of follow up 
F-up = follow up in years 
ROV-MORT = Risk of overall mortality at year of follow up 
RC-MORT = Risk of cancer mortality at year of follow up 
RC-MORT 10 yrs = Risk of cancer mortality 10 year after treatment 
1 disease specific survival 
2 early toxic death 5: neutropenic infections (decreased white blood cells) and septic multi-organ 
failure. HD toxic death: any death occurring within 100 days from grafting and not directly related 
to the disease itself 
 
Harm 
Early treatment related mortality was 3% for patients treated with SD-CT in a 
RCT 17. This is concordant with an early treatment related mortality of 3% 
reported in other series 18,19. HD-CT early treatment related mortality was 4%. The 
European Group for Blood and Marrow Transplantation (EBMT) Solid Tumours 
registry has recently reported an update of the mortality rate of germ cell tumour 
patients treated in Europe between 1990 and 1999. The rate of toxic death, 
defined as any death occurring within 100 days from grafting and not related to 
the disease itself, declined from 8% in 1990 to 3% in 1999 (overall 5%) 19. We 
estimate the excess early treatment mortality as 1% (4-3%).  
Table 2 lists the most common complications due to treatment of non-
seminomatous germ cell cancer 10,20. For each complication the incidence for SD-
CT and HD-CT is given and the suspected agent. Leukaemia is the main cause of 
late treatment mortality in patients treated for NSGCT. More patients are 
expected to develop leukaemia after HD-CT than SD-CT (1.5 vs. 0.5%). With a 
mortality of 70% for leukaemia, this results in a difference in late treatment 
mortality of 0.7% 10,21,22.  
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Table 2 Incidence, mortality and utility of long term complications due to 
high-dose (HD) or standard-dose (SD) chemotherapy for nonseminomatous 
germ cell cancer 
Morbidity  
(references) Incidence 
Suspected 
agent 
Mort ∆ Mort3 Utility4 ∆ Morb5 
 SD HD      
Therapy 
related 
leukaemia  
(10,21,22) 
0.5% 1.5% 
Etoposide 
(< 2 g/m2  
> 2 g/m2) 
70% 0.7% 0.90 0.03% 
Vascular 
toxicity  
(10,15,23,24) 
       
Raynaud’s 
phenomenon 
25% >25% Bleomycin   - - 
Cardiovascular 
disease 
7% 10% Cisplatin 10% 0.3% 0.7 0.81% 
Neurotoxicity  
(5,10,20)        
Peripheral 
neuropathy 
4% 5% Cisplatin   - - 
Ototoxicity 5% 65% 
Cisplatin  
(<400 mg/m2,  
> 400 mg/m2) 
  - - 
Nephrotoxicity  
(5,10,15)        
Renal failure 1% 4% Cisplatin   0.6 1.2% 
Hypertension 10% 24% 
Cisplatin  
(<400 mg/m2,  
> 400 mg/m2) 
  0.99 0.14% 
Gonadal 
toxicity  
(10,15,25,26) 
       
Infertility1 50% >50% Cisplatin     
Sexual 
functioning2 
15% 27%    0.92 0.96% 
Total     1%  3.14% 
1 oligospermia/azoospermia 
2 sexual dissatisfaction 
3 ∆ Mortality calculated as (incidence HD-CT – incidenceSD-CT) x fatality 
4 Utility ranges from 0-1and is a measure of health related quality of life 
5 ∆ Morbidity calculated as (incidence HD-CT – incidence SD-CT) x (1-U) x (1-fatality) 
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Cardiovascular disease further contributes to treatment mortality of patients 
treated for NSGCT 10,23,24. The incidence of cardiovascular disease is estimated as 
7% for SD-CT patients. We estimated the incidence of cardiovascular disease at, 
10% for HD-CT patients, although no firm empirical estimates were available for 
HD-CT. With a fatality of 10% this results in 0.3% excess mortality. The 
combination of early and late treatment related mortality resulted in an estimated 
harm of 2%.  
Other long term complications vary from relatively mild (Raynaud’s phenomenon, 
ototoxicity) to severe (renal failure) 5,10,26. In estimating the difference in long term 
morbidity between SD-CT and HD–CT we only took the more severe 
complications into account. No utility was known for acute myeloid leukaemia. 
Although physical and emotional functioning of long term leukaemia survivors is 
near normal, sexual functioning and fertility is often affected 27. We therefore 
estimated a utility of 0.9 for treatment related leukaemia. 
Figure 2 Linear benefit (30%) and nonlinear benefit (30%) vs. harm of high-dose 
chemotherapy, with harm defined as 10-year treatment related mortality (2%) or 
mortality plus morbidity (5%). The arrows indicate the thresholds to define poor 
prognosis (7% and 17% respectively for linear benefit, 4% and 11% respectively 
for nonlinear benefit) 
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The overall difference in utility weighted long term morbidity was 3.1%. The total 
harm due to HD-CT was approximately 5% (excess mortality 2% + excess 
morbidity 3.1%).  
 
Treatment thresholds for HD-CT  
At a benefit of 30% and only treatment related mortality included in our estimate 
of harm (2%), patients with only 7% risk of cancer mortality or higher should be 
treated with HD-CT (Figure 2). With a benefit of 40% the treatment threshold was 
as low as 5%.  
When we also take treatment related morbidity into account in our estimate of 
harm (5%) and benefit is 30%, patients with a 17% risk of cancer mortality or 
higher should be treated with HD-CT (Figure 2). With a benefit of 40% the 
treatment threshold was 12.5%. 
When we assumed a nonlinear benefit of 30% and a harm of either 2 or 5% 
treatment thresholds were 4 and 11% respectively (Figure 2). With a nonlinear 
benefit of 40% threshold values were below 10% (3 and 8% respectively).  
The estimates of benefit and harm determine the treatment thresholds as shown 
in Figure 3 for treatment benefits from 0 to 50% and harms from 0% to 40%. For 
nonseminomatous germ cell cancer patients an estimated benefit of 30% and 
harm of 5% resulted in a threshold of 17% (block 1). When we assumed a benefit 
of 40%, with the same harm of 5%, the threshold decreased to 12.5% (block 2). 
The same threshold could be obtained with a smaller benefit, and a much smaller 
harm, for example 10% and 1% (block 3). We could also consider more harmful 
therapies, which would naturally only be considered for types of cancer with a 
very poor prognosis. With harm as high as 20% and a benefit of 50%, the 
treatment threshold for such patients is a 40% risk of cancer mortality (block 4). 
 
6.4 Discussion  
We illustrated how decision analysis can explicitly assist in defining poor 
prognosis testicular cancer patients who have a net benefit of high-dose 
chemotherapy (HD-CT) with stem cell support. Based on the currently available 
literature we considered a conservative estimate of 30% for the benefit and an 
optimistic estimate of 40%. We estimated a harm of 5%, based on both treatment 
mortality (2%) and treatment morbidity expressed in utilities (3%). Even with a 
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conservative estimate of 30% for the benefit of treatment, and taking both 
treatment related mortality and morbidity into account, patients with a risk of 
cancer mortality of 17% or higher might already benefit from HD-CT. With a 
benefit of 40% this threshold was reduced to 12.5%. When we assumed benefit 
to be nonlinear, treatment thresholds were 11 and 8% for benefit of 30 and 40% 
respectively. 
Relative risk (1-benefit)
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Treatment thresholds
Figure 3 Thresholds according to risk with standard treatment for a range of 
hypothetical benefits (reduction in relative risk, RR) and harms associated with a 
more intensive treatment.  
1. benefit 30%, harm=5%, threshold=17% (− − −) , 2. benefit 40%, harm=5%, 
threshold = 12.5% (  ), 3. benefit 10%, harm=1%, threshold = 12.5% (  ), 4. 
benefit 50%, harm=20%, threshold = 40% ( - - - ). 
 
To what extent is the group of patients above the threshold comparable to the 
poor prognosis patients as defined by the IGCC classification? The 5-year survival 
for the good, intermediate and poor prognosis patients was originally reported as 
92, 80 and 48% respectively 11. However, year of treatment was ignored, and 
2154 out of 5202 patients with missing values were discarded from the analysis. 
We have recalculated the expected survival for the IGCC prognosis groups with 
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statistical adjustment to the year 1990 and with consideration of all 5202 patients 
by imputation of missing values, and found 10-year estimates of 93, 84 and 57% 
respectively 28. These numbers are confirmed in more recently reported series 
13,16. Also with these revised estimates, risk of death from cancer in the poor 
prognosis group is clearly above the threshold, confirming that these patients are 
likely candidates for HD-CT.  
The patients in the intermediate prognosis group have mortality risks around the 
threshold. We previously modelled the 5 risk factors of the IGCC classification in 
more detail in a Cox regression model 29. The risk estimates from this model show 
some spread for the 862 patients classified as intermediate prognosis: 580 (67%) 
have risks lower than 17%, and 282 (33%) have risks higher than 17%. However, 
only 97 (11%) had 10-year mortality risks higher than 20%, which would more 
strongly support considering them for HD-CT. On the other hand a minor fraction 
of the IGCC category ‘poor prognosis’ had modelled risks below 17% (43/495, 
9%). 
The IGCC classification and our decision analysis hence largely agree on which 
patients are candidates for HD-CT. In the future, a more refined prognostic 
classification is however desirable, with prognostic groups defined in more detail 
and with more powerful predictors, e.g. new biomarkers 30,31. 
Although we considered a conservative and optimistic estimate of the benefit of 
HD-CT our estimate may still be too optimistic. Differences in treatment other 
than HD-CT may have affected the difference in survival between patients treated 
with SD-CT and patients treated with HD-CT. Firstly the patients treated with SD-
CT were mainly treated in the US whereas patients treated with HD-CT were 
treated in Germany. However, the estimated risk of cancer mortality for SD-CT is 
in line with the IGCC survival estimate for poor prognosis patients adjusted for 
year of treatment, which is based on patients treated in both Europe and the 
US 28. Secondly, patients treated with SD-CT were treated earlier than patients 
treated with HD-CT. Improvements over time in second line treatment may have 
effected the difference in survival 17. 
Our estimate of harm may be too low. We estimated harm due to treatment 
related mortality and morbidity at 10 years after treatment. Direct estimates of 
early treatment mortality were available for both SD-CT and HD-CT. However 
information on long term complications is merely available for SD-CT, and limited 
for HD-CT. As a consequence our estimate of etoposide induced leukaemia, 
which is very difficult to cure, may be too low.  
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Similarly, the harm due to complications such as cardiovascular disease and 
hypertension may be higher since they pose a lifetime risk. Finally, little is known 
about the harm due to chronic fatigue and neuropsychological sequelae 17. Figure 
3 helps to directly calculate the risk threshold if more conservative assumptions 
are made. For example, when the relative risk reduction due to HD-CT is only 
20% and the harm 8%, only patients with at least a 40% risk will benefit from 
more intensive treatment. 
Our analysis has some other limitations. To compare harm and benefit of HD-CT 
we expressed both in 10-year risks, without considering the time of the event 
since treatment (early or late). This is a simplification. An alternative would be a 
more extensive decision analysis, in which expected life years and the probability 
of complications are modelled, e.g. with a Markov model with yearly cycles 32. 
However given the uncertainty in the estimates of harm and benefit such a more 
complicated model was not considered desirable.  
We also did not consider costs of HD-CT or SD-CT. There are currently no data 
available on the difference in costs between HD-CT and SD-CT for testicular 
cancer patients but in other diseases, such as non-Hodgkin’s lymphoma, multiple 
myeloma and breast cancer, the costs of HD-CT have been reported to be one to 
four times higher than SD-CT 33. Hence, HD-CT needs to have a substantial net 
benefit to be relevant from a societal perspective. 
Evidence of the benefit of HD-CT as first line treatment in the literature has not 
been conclusive, and the results of two ongoing RCTs have to be awaited for 
more reliable decision making. One RCT by the EORTC (BEP vs. high-dose VIP) is 
still including poor prognosis patients 8. The inclusion of intermediate and poor 
prognosis patients for an RCT by the US intergroup (BEP vs. high-dose CEC) has 
closed and preliminary results have been presented 9,34. There was no significant 
difference in complete response after 1 year between standard and high-dose 
chemotherapy (48 vs. 52%). We will have to await the publication of the final 
results of these RCTs before a more precise estimate of the benefit of HD-CT can 
be made. 
Based on the number of patients enrolled in these trials, a relative risk reduction 
over approximately 50% can be detected with sufficient statistical power. This 
may be an optimistic estimate, and results of the trials may be inconclusive when 
HD-CT in fact has a smaller effect. Our analysis suggests that HD-CT may not be 
beneficial for the full group of intermediate prognosis patients, especially because 
of excess long term mortality and morbidity. Special attention should be given to 
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the intermediate prognosis patients in the analysis of the RCT that includes these 
patients 9. Further, it is important that more precise information becomes available 
on the long term complications of HD-CT by longer follow up, since testicular 
cancer occurs mostly at a young age. 
Besides HD-CT other approaches are being investigated to improve survival of 
NSGCT patients, such as dose intensification and the introduction of new 
agents 35-37.  
A recently published phase II trial investigating the intensive induction 
chemotherapy carboplatin, bleomycin, vincristine, cisplatin + bleomycin, 
etoposide, cisplatin (C-BOP/BEP) showed promising results with 2-year survival of 
94 and 85% for intermediate and poor prognosis patients respectively. However, 
2-year progression free survival was much lower for poor prognosis patients 
(56%) suggesting that the benefit will be smaller at 5 or 10-year follow up 38.  
Furthermore the EORTC currently conducts a RCT targeted especially at 
intermediate prognosis patients which investigates the combination of paclitaxel 
with BEP (T-BEP) 39. The results of these trials can be incorporated in the decision 
analytic approach described in this study to determine which treatment is optimal 
at what harm and benefit.  
In conclusion, we illustrated how decision analysis can support treatment choices 
on more intensive therapy. From the decision analysis we learn at what risk a 
treatment becomes beneficial. A prognostic model or prognostic classification can 
then be used to estimate the risk of an individual patient or a subgroup of 
patients. This approach can be adapted to new results from ongoing trials and 
extended to many other cancers to explicitly define candidates for more intensive 
treatments. Hence, patients who are expected to benefit will be treated more 
intensively, without overtreatment of those at relatively low risk, and patients who 
are not expected to benefit will be treated in a more standard way, without 
undertreatment of those at relatively high risk.  
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This thesis describes methodological aspects of prognostic classifications in 
oncology, using the IGCC classification for patients with nonseminomatous germ 
cell cancer for illustration. 
We evaluated the validity of the IGCC classification, with respect to assumptions 
made in the development of the classification and the generalisability of the 
survival estimates for currently diagnosed patients. Furthermore we studied 
alternative ways of defining prognostic groups, especially for poor prognosis 
patients. 
In this chapter the findings of our studies are discussed according to the research 
questions as specified in Chapter 1. We end with conclusions and 
recommendations for future research. 
 
7.1 Answers research questions 
 
Research question 1: Are the assumptions made in the development of the IGCC 
classification valid with regard to the inclusion of prognostic factors, or can 
discriminative ability be improved? 
Answer: Incorporating differences in predictive strength, or specifying interaction 
terms did not result in an increase in discriminative ability over the original IGCC 
classification. Hence we support the validity of the IGCC classification to define 
prognosis groups.  
 
Explanation: The IGCC classification did not consider differences in strength of 
prognostic factors and made no distinction between the number of prognostic 
factors within a prognosis group. Better discrimination might be achieved by 
incorporating differences in predictive strength and testing specific interaction 
terms. 
Differences in predictive strength: Simplifications in the modelling process, such 
as categorising continuous risk factors and using strongly rounded regression 
weights, are usually regarded as undesirable as the associated loss in information 
can result in a decrease in predictive performance 1,2. Our Cox regression analysis 
demonstrated differences in predictive strength between the IGCC prognostic 
factors. But an alternative classification that took these differences into account 
did not perform better than the IGCC classification in defining a poor, an 
intermediate and a good prognosis group.  
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Of the 3048 patients with complete data, 204 patients (7%) were classified 
differently by the Cox regression model compared to the IGCC classification; 97 
intermediate prognosis patients were reclassified as poor prognosis, while 107 
poor prognosis patients were reclassified as intermediate prognosis (Figure 1). 
However, 5-year survival of these patients was identical (69 vs. 69%), and re-
classification did hence not result in a better performance. So, the differences 
could affect the patient at the individual level with respect to treatment choice 
but did not change the overall performance. 
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Figure 1 Classification of 3048 nonseminomatous germ cell cancer patients in the 
IGCC database according to the IGCC classification and a Cox regression based 
classification 
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Interactions between IGCC prognostic factors: Regression models assume 
additivity of the effects of their prognostic factors 2. The effect of a prognostic 
factor is assumed not to modify the effect of other prognostic factors. In Cox 
regression, additivity refers to the additivity of regression coefficients on the log 
hazard scale. Non-additivity is taken into account by including interaction terms in 
the regression model. Usually we only consider two-way interactions, where a 
significant interaction term indicates that the effect of the prognostic factors 
together is smaller or larger than the sum of separate effects of two prognostic 
factors. 
The IGCC classification considers the presence of more than one intermediate or 
poor prognostic factors as equal to having only one intermediate or poor 
prognostic factor respectively. This is an example of a ‘max rule’, which assumes a 
negative interaction between prognostic factors. We tested the implicit non-
additivity assumption in the IGCC classification in two ways. Interaction terms 
were included in Cox regression models. And we applied regression tree 
modelling which is very suitable of capturing non-additive effects of prognostic 
factors 3. 
Both methods showed that the tumour marker AFP was less important than the 
other IGCC prognostic factors, while the IGCC classification assumed that all 
prognostic factors were equally important. The tree model did not include AFP, 
while in the Cox regression analysis the effect of AFP was modified by the 
presence of primary site and NPVM. The limited contribution of AFP was also 
demonstrated by the much lower weight of AFP, indicating less predictive 
strength, in the regression based classification. The alternative classifications did 
not classify patients better than the IGCC classification in terms of discriminative 
ability. 
There were some limitations in testing the non-additivity assumption of the IGCC 
classification. Tree modelling only allows for binary splits of variables. The tumour 
markers were split in the categories good/intermediate vs. poor, which limits 
comparability with the IGCC classification in which all three tumour marker 
categories are considered. Second, in a Cox regression analysis only two-way 
interactions can readily be interpreted, while the IGCC classification assumes 
more complicated higher order interactions between the prognostic factors. 
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Research question 2: What is the effect of missing values on survival estimates of 
the IGCC classification? 
Answer: Multiple imputation of the missing values in the IGCC database led to 
lower survival estimates across the IGCC prognosis groups, compared with 
estimates based on the complete data. This was explained by a correlation 
between missingness and year of treatment, while year of treatment was 
associated with survival. 
 
Explanation: In the development of the IGCC classification 2154 (41%) of 5202 
patients were excluded. Remarkably, only 2388 (9%) of all 26010 required data 
values of the 5 IGCC risk factors were missing (5 x 5202). Imputation of the 9% 
missing values added 32% observed values to the analysis. Exclusion of patients 
because of missing data was statistically inefficient. Moreover, it could have led to 
bias in the survival estimates of the prognostic groups in the IGCC classification if 
missingness was not completely at random 4. Patients with missing values had 
poorer survival. 
Missingness was mostly caused by missing values for LDH. This tumour marker 
was not systematically collected by all participating centres before 1985, since its 
prognostic value was not yet fully recognized at that time.  
Imputation of missing values resulted in lower survival estimates across the IGCC 
prognosis groups, compared with the analysis of the 3048 patients with complete 
data. This difference could largely be explained by year of treatment, since an 
earlier year of treatment was both related to missingness and to a lower survival. 
Year of treatment hence acted as a kind of confounder (Figure 2).  
The imputation of missing values made us aware of the relevance of year of 
treatment, independent of the use of complete case analysis as the statistical 
method to handle missing values. The survival estimates reported by the IGCCCG 
are therefore not valid for current patients, and should be adjusted for year of 
treatment. 
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Figure 2 Relation between missing values and survival. Patients in the IGCC 
database with missing values have a lower survival than patients with no missing 
values (a). This difference is explained by year of treatment; patients with missing 
values were treated earlier, when survival was lower (b) 
 
Handling of missing values in prognostic studies: A recent review demonstrated 
that missing values are a common problem in prognostic studies in oncology 5. In 
this review 100 articles were considered, published in 2002 and selected from 7 
clinical cancer journals with high impact factors 
Missing values occurred in almost all studies reviewed. In 81 articles missing 
values were present, and another 13 articles had availability of data as an 
inclusion criteria but did not report how many patients were excluded. In 52 
articles the number of missing values for each variable was given, while the 
number of complete cases used for analysis was given in only 39 studies.   
When a method for handling missing data was reported this was most often 
complete case analysis. Three articles used single imputation, while only one 
article used multiple imputation. Finally, the possible reasons for missingness were 
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discussed in 21 articles, while only 10 studies investigated possible differences in 
characteristics or outcome between patients with and without missing values. 
These results show that many researchers are not fully aware of how to deal with 
missing values in prognostic studies. Guidelines were proposed for reporting 
prognostic studies with missing data (Table 1) 5. Table 1 shows that the proposed 
guidelines focus on 3 main issues: quantification of the completeness of predictor 
data, approaches to dealing with missing predictor data (including imputation 
methods), and exploration of the missing data (e.g. comparing for complete and 
incomplete cases).  
 
Table 1 Guidelines for reporting prognostic studies with missing covariate 
data 5 
Quantification of completeness of covariate data 
• If availability of data is an inclusion criterion, specify the number of patients 
excluded for this reason 
• Provide the total number of eligible patients and the number with complete 
data 
• Report the frequency of missing data for every variable considered 
Approaches for handling missing covariate data 
• Provide sufficient details of the methods adopted to handle missing 
covariate data for all incomplete covariates 
• Give appropriate references for any imputation method used  
• For each analysis, specify the number of patients included and the 
associated number of events 
Exploration of the missing data 
• Discuss any known reason for missing covariate data 
• Present the results of any comparisons of characteristics between the cases 
with and without missing data. 
 
Use of imputation techniques: Multiple imputation is a state of the art method 
for handling missing data. It is preferred over single imputation since it takes the 
uncertainty of the imputed values into account.  
However, the application of multiple imputation is complex and requires 
knowledge of advanced statistical software. Under certain conditions single 
imputation may therefore be a reasonable method for handling missing data. 
Also, a complete case analysis can sometimes be performed.  
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Complete case analysis could be applied when all of the following conditions are 
met: 
• The number of missing values (per variable) is limited, and therefore the 
number of excluded patients is small (e.g. <10%) 
• There is no difference in outcome or patient characteristics between 
patients with and without missing values  
• Missing values can be considered missing completely at random (MCAR), 
i.e. they are a random sample of the whole dataset. 
Multiple imputation should be applied when any of the following occurs: 
• The number of missing values (per variable) is large resulting in the 
exclusion of many patients (e.g. >30%). 
• There is a substantial difference in outcome of patients with and without 
missing values 
Single imputation can be considered for intermediate situations, e.g. around 20% 
missing values, but not completely at random. Any imputation method (single or 
multiple) has to assume that missing values are missing at random (MAR). This 
means that missingness only depends on other variables in the dataset. The MAR 
assumption is not testable, but becomes more reasonable with imputation models 
that include a wide range of characteristics, including all potential prognostic 
factors, auxiliary variables (such as year of treatment or treatment centre), and the 
outcome (e.g. survival time and the censoring variable) 6. 
Including the outcome may appear a bit circular, since the aim of a prognostic 
model is to predict outcome. However, it can easily be shown that not including 
the outcome in the imputation model causes bias, even in the MCAR situation. 
 
Research question 3: Has survival of patients with advanced testicular cancer 
improved since the introduction of the IGCC classification? 
Answer: Yes, survival estimates reported by the IGCC investigators are lower than 
survival of patients currently diagnosed with advanced testicular cancer. 
 
Explanation: The survival estimates of the IGCC classification were based on 
patients treated between 1975 and 1990. A systematic review of the literature on 
studies reporting on survival of patients with nonseminomatous germ cell cancer 
treated after 1989 showed an increase in survival especially for poor prognosis 
patients. For these patients we estimated a 5-year survival of 71% instead of 48%. 
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Even within the IGCC data survival increased over time; when survival estimates 
were adjusted in a Cox model for the last year of treatment (1990) 5-year survival 
was 61% for poor prognosis patients (Figure 3). 
The increase in survival for poor prognosis patients is most likely due to more 
effective treatment and to more experience in treating patients with 
nonseminomatous germ cell cancer 7. Which of these factors is most responsible 
for the increase in survival, should become clear from randomised controlled 
trials. In such trials patients in both treatment arms profit from improved 
experience in treating patients, and hence a pure effect of treatment can be 
determined. 
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Figure 3 Survival estimates of poor prognosis nonseminomatous germ cell cancer 
patients according to a) a meta-analysis of available literature on patients treated 
since 1990 (5-year survival 71%), b) patients in the IGCC database adjusted for 
year of treatment 1990 (5-year survival 61%), c) patients in the IGCC database (5-
year survival 48%) 
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Implications for interpretation of clinical trials: Survival estimates from the IGCC 
data 8 are currently the historical control for the comparison of results from 
nonrandomised Phase I/II trials in which new treatment strategies for patients with 
advanced testicular cancer are studied. However, this comparison leads to a too 
optimistic impression of a new treatment, since the survival of currently 
diagnosed patients is most likely better than reported by the IGCC investigators. 
We can assume that 5-year survival of poor prognosis patients diagnosed 
nowadays will lie between 61 and 71%. However, a more reliable estimate can 
be obtained from patients treated with standard chemotherapy in current RCTs. 
Until then, results of nonrandomised trials should not be compared with the 48% 
reported by the IGCCCG. 
 
Research question 4: Is regression tree analysis an appropriate method for further 
subgrouping within poor prognosis patients? 
Answer: No, regression tree analysis leads to unstable and optimistic models, and 
is therefore not appropriate for identifying subgroups in prognostic classifications. 
 
Explanation: Regression tree analysis is a nonlinear method to define groups of 
patients differing in prognosis. It is more flexible than standard regression 
approaches, especially in detecting complex interactions between prognostic 
factors. The German Testicular Cancer (GTC) group used this method for further 
subgrouping of poor prognosis patients to allow for a more refined identification 
of individuals patients at high risk, eligible for high-dose chemotherapy 9.  
Predictive performance of this tree was lower than expected when applied to the 
IGCC data. A new tree model developed with similar methods as the GTC group 
differed in the selection and hierarchy of prognostic factors. Internal validation of 
this new tree showed a large degree of optimism in performance. 
 
Linear modelling versus nonlinear modelling: In our analyses, prognostic 
classifications based on linear models (Cox regression) outperformed prognostic 
classifications based on nonlinear models (regression tree analysis) both in small 
(n=332) and large (n=3048) datasets (Chapters 5 and 2 respectively).  
Previous studies confirm that linear models may perform just as well or better 
than nonlinear models in prognostic studies. Ennis et al (1998) compared a 
previously developed logistic regression model to predict 30-day mortality, based 
on 40830 patients, with nonlinear models such as tree models and neural 
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networks 10. They found that the nonlinear models did not outperform the 
relatively simple logistic regression model. 
Similar results were found in another study in which the performance of Cox 
regression was compared with regression tree analysis and neural network in 3 
large urological datasets (prostate cancer and renal cell carcinoma) 11. Both 
studies conclude that these datasets apparently did not include highly predictive 
nonlinear or interaction effects, and that maximum performance could be 
reached by using a relatively simple linear model. We may wonder how often 
such complex effects occur in the real world, and when they are not predefined, 
whether we can capture them without overfitting our models to our data. 
Further advantages of the Cox regression model over tree models and neural 
networks include insights in the prediction model (e.g. hazard ratios, significance 
testing) and its reproducibility. The same results are obtained each time Cox 
regression is applied to a dataset, while nonlinear modelling strategies may give 
different results because random processes are sometimes used in determining 
the final model. 
We therefore suggest to use tree modelling for exploratory purposes only to 
detect possible interaction effects, which could then be considered in a regression 
model 12.  
 
Research question 5: At what risk of cancer-mortality should patients with 
advanced testicular cancer be treated with high-dose chemotherapy?  
Answer: With current estimates on benefit and harm of high-dose chemotherapy, 
patients with a risk of cancer mortality of 17% or higher might profit from high-
dose chemotherapy. 
 
Explanation: Based on evidence available in the literature we estimated the 
benefit of high-dose chemotherapy (HD-CT) with autologous stem cell support for 
patients with advanced testicular cancer at 30%, i.e. HD-CT results in relative 
reduction in risk mortality of 30%. Harm was estimated at 5%, i.e. treatment with 
HD-CT leads to an increase in absolute risk of mortality of 5%. Combined in a 
decision analysis this resulted in a treatment threshold of 17% risk of cancer 
specific mortality with SD chemotherapy. This threshold leads to a similar 
selection of patients as defined by the IGCC classification for poor prognosis 
patients. 
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The IGCCCG investigators considered several aspects in deriving their poor 
prognosis group. It should be simple to define, have a relatively low 5-year 
survival, and contain a sufficiently large number of patients. The latter aspects 
reflect a research perspective and not necessarily the patient’s perspective. In 
decision making for individual patients, the net effectiveness of a therapy is of 
interest. This is based on weighing benefits of treatment, such as lower cancer-
specific mortality, against harm of treatment, such as toxic side effects, burden, 
and long term risks (e.g. cardiovascular morbidity and mortality). The point where 
benefits and harms are equal is the treatment threshold. Decision analysis 
provides an appropriate and useful framework to define such treatment 
thresholds in prognostic classifications. Our estimates of benefit and harm of high-
dose chemotherapy in ‘poor prognosis patients’ are yet to be confirmed in future 
studies. Benefit was based on results from nonrandomised trials, while there was 
only limited information available on long term harm of high-dose chemotherapy. 
 
Ongoing randomised clinical trials: New treatment strategies are under study for 
the treatment of patients with advanced testicular cancer. Benefits and harms of 
these new treatments may differ from those of high-dose chemotherapy. 
Therefore, the IGCC poor prognosis definition might not always be appropriate to 
allocate patients to such treatments. Decision analysis can be used to determine a 
treatment threshold for each pair of treatments.  
To determine these thresholds reliable estimates of benefit and harm are 
necessary. Such estimates are ideally based on RCTs. Only preliminary results are 
available from current RCTs. 
For high-dose chemotherapy, two different approaches are being considered. First 
results of a treatment strategy investigated by the US intergroup (standard 
chemotherapy vs. two cycles of BEP plus two cycles of high-dose carboplatin, 
etoposide, cyclophosphamide with stem cell support) were presented at the 2006 
American Society of Clinical Oncology (ASCO) conference 13. There was no 
significant difference in complete response after 1 year between standard and 
high-dose chemotherapy (48 vs. 52%). This is in contrast with results from earlier 
nonrandomised studies, in which patients who received this treatment compared 
favourably to historical controls. Furthermore, the low complete response at 1 
year suggests that 5-year survival will be lower than expected from our analyses 
(Figure 3). This is especially remarkable, since this study also included 
intermediate prognosis patients.  
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The German approach consists of standard treatment vs. one cycle cisplatin, 
etoposide, ifosfamide (VIP) followed by three cycles of high-dose VIP, and was 
used as an example in Chapter 5. It is studied in an European trial 14. By May 
2006 135 of the required 222 patients were accrued. First results are expected in 
2009. 
Other approaches are the addition of active drugs to standard treatment, 
alternating chemotherapy to prevent drugs resistance and dose dense sequential 
combination chemotherapy 15-17. RCTs studying these treatments are still including 
patients, and results are not expected before 2008. This overview of ongoing 
trials demonstrates that the relative rarity of testicular cancer makes accrual of 
patients difficult, even though in all trials multiple centres collaborate in all these 
trials.  
An even bigger challenge in determining treatment thresholds is to obtain reliable 
estimates of long term benefits and harms for these treatments. Limited 
information is available on risk up to 10 years, such as leukaemia, neurotoxicity 
and gonadal toxicity. Even less is known, both for standard treatment and 
alternative treatment strategies, about mechanisms influencing life long risk of for 
instance cardiovascular disease through hypertension and hypercholesterolaemia. 
 
Table 2 Ongoing randomised controlled trials in patients with 
nonseminomatous germ cell cancer1 
Protocol ID Prognosis 
group 
Treatment Status Start – end N 
req 
N 
ent 
EORTC-30974 14 Poor High-dose VIP  Active 1999 - 2009  222 135 
EORTC-30983 16 Interm. T-BEP  Active 1998 - 2008 498 300 
MRC-TE23 15 Poor CBOP/BEP  Active 2005 - 2008 84 18 
FNCLCC-13/0206 17 Poor BEP+dose dense CT Active 2005 - 2012 240 55 
MSKCC-94076 13 Poor/ 
Interm. 
BEP + HD-
carboplatin based CT  
Closed 1999 - 2001 270 270 
1 Personal communication trial leaders, May 2006. 
EORTC = European Organisation for research and treatment of cancer 
MRC  = Medical Research Council Clinical Trial Unit 
MSKCC = Memorial Sloan-Kettering Cancer Center 
FNCLCC = Federation Nationale des Centres de Lutte Contre le Cancer 
VIP = cisplatin, etoposide, ifosfamide 
BEP = bleomycin,  etopside, cisplatin 
T-BEP = Taxol, bleomycin, etopside, cisplatin 
CBOP/BEP = cisplatin, vincristine, bleomycin, carboplatin/bleomycin,  etopside, cisplatin 
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7.2 Conclusions and recommendations for future research 
 
Methodological aspects of prognostic classifications 
 
Conclusions 
 
• Prognostic classifications should preferably be based on regression 
analysis, since this method is transparent, reliable and generalisable to 
other patients. Tree models might be used for exploratory purposes, to 
investigate possible interactions between prognostic factors. 
 
• In the development of prognostic classifications missing values should be 
accounted for to prevent statistical inefficiency and (possible) bias. 
Depending on the research question, how many values are missing and 
the missing data mechanism, either complete case, single or multiple 
imputation might be used as a method for handling missing data. 
 
• When a prognostic classification is developed with data collected over a 
long calendar period, there is possibly an increase of survival over time.  
 
• Classifications may remain valid over longer periods to discriminate 
between good prognosis and poor prognosis patients, but require regular 
updating of prognostic estimates such as predicted 5-year survival. 
 
• Decision analysis provides an appropriate and useful framework to define 
treatment thresholds in prognostic classifications. 
 
Recommendations for future research 
 
• More research is needed on how tree models can aid in detecting 
complex relationships between prognostic factors and how this can be 
used in the development of prognostic classifications. 
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• Single and multiple imputation should be compared in empirical studies 
to determine under what conditions single imputation is sufficient for 
handling missing data. 
 
Prognosis in advanced testicular cancer 
 
Conclusions 
 
• The relatively simple IGCC classification performed just as well as more 
complex alternatives. The IGCC classification is a valid method for 
distinguishing good and poor prognosis patients with advanced testicular 
cancer. 
 
• The IGCC classification underestimates survival of currently diagnosed 
patients with advanced testicular cancer. The results of nonrandomised 
trials should not be compared with the survival estimates reported by the 
IGCCCG. Instead updated estimates adjusted for year of treatment or 
based on our literature review should be used.  
 
• Tree modelling is not an appropriate method for subgrouping the poor 
prognosis patients with advanced testicular cancer. 
 
Recommendations for future research 
 
• Our estimates of survival of currently diagnosed advanced testicular 
cancer patients should be confirmed by ongoing trials. 
 
• The prognostic value of the rate of tumour marker decline during 
treatment and genetic markers should be determined. These prognostic 
factors might allow for a more refined and dynamic assessment of 
prognosis of patients with advanced testicular cancer. 
 
• Follow up of patients with advanced testicular cancer is needed to 
determine long term benefit and harm of both standard treatment and 
alternative treatment strategies. 
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Patients with similar characteristics can be grouped together in a prognostic 
classification to estimate a patient’s prognosis and guide treatment decisions. The 
topic of this thesis is methodological aspects of defining prognosis classifications. 
We specifically looked at patients with advanced testicular cancer, who are 
currently classified into good, intermediate and poor prognosis groups according 
to the International Germ Cell Consensus (IGCC) Classification. The IGCC 
classification aims to guide treatment decisions, it is used as a stratification 
method for clinical trials. 
Two main topics are investigated: (1) the validity of the IGCC classification: are 
the assumptions underlying the IGCC classification method valid and can the 
survival estimates of the IGCC classification be generalised to currently diagnosed 
patients, (2) alternative methods of defining prognostic groups, especially for 
poor prognosis patients. 
 
Validity of the IGCC classification 
Issues in the development of prognostic classifications are discussed, and 
background on testicular cancer and the development of the IGCC classification 
is given in Chapter 1.  
Chapters 2, 3 and 4 describe studies on the validity of the IGCC classification, 
with respect to the assumptions made in the development of the IGCC 
classification (Chapters 2 and 3) and the generalisability of the survival estimates 
of the IGCC classification to currently diagnosed patients (Chapters 3 and 4).  
 
The IGCC classification assumes that all prognostic factors are equally important 
in predicting a patient’s prognosis. Furthermore, within a prognosis group no 
distinction is made in the number of adverse prognostic factors for a patient. 
Chapter 2 looks at whether incorporating differences in importance between 
prognostic factors and considering the number of adverse prognostic factors 
within a prognosis group improves the performance of the IGCC classification.  
We therefore developed alternative classifications for the 3048 patients in the 
IGCC database based on both Cox regression analysis and tree modelling, and 
evaluated their performance.  
Both methods demonstrated that there are differences in importance between the 
prognostic factors in the IGCC classification. Furthermore, within a prognosis 
group, prognosis differs for patients with different numbers of adverse prognostic 
factors.  
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This, however, did not result in a relevant increase in performance compared 
relative to the original IGCC classification. Hence we support the validity of the 
IGCC classification is reasonably valid to define prognosis groups.  
 
In the development of the IGCC classification 41% of patients were excluded 
because of missing values. These values were mainly missing in the tumour 
marker LDH.  
The effect of excluding these patients on the survival estimates in the IGCC 
classification was investigated in Chapter 3 by filling in the missing values using a 
multiple imputation technique.  
After multiple imputation, 5-year survival was lower for the group of patients with 
missing values than for the group of patients without missing values. We could 
explain the difference in survival between patients with and without missing 
values as follows. 
For patients with advanced testicular cancer in general, and hence those in the 
IGCC database, average survival probability increased over time. However, year 
of treatment is not a prognostic factor used in the IGCC classification, nor is 
improvement in treatment accounted for in any other way. As a result, the 
survival estimates of the IGCC classification are too low for more recently treated 
patients. Because missing values were mainly found in relatively historical 
patients, multiple imputation led to a further underestimation of survival in the 
IGCC classification when no adjustment for year of treatment was made. 
 
In Chapter 4 we investigated whether survival estimates of patients with 
advanced testicular cancer increased further since the introduction of the IGCC 
classification in 1997.  
We did a systematic search of the literature and found ten studies on survival of 
patients treated after 1989, with advanced testicular cancer, with outcome 
reported according to the IGCC classification. These ten studies describe a total 
of 1775 patients. We pooled the estimates of the selected studies using meta-
analytic techniques.  
Pooled 5-year survival estimates were 94, 83 and 71% for good, intermediate and 
poor prognosis patients respectively. The original IGCC classification reported 
lower 5-year survival estimates (92, 80 and 48% respectively). The large increase 
in survival for the poor prognosis patients is most likely due to more effective 
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treatment strategies and more experience in treating patients with advanced 
testicular cancer. 
 
Chapters 3 and 4 demonstrated that survival estimates reported by the IGCC 
classification are not valid for currently diagnosed patients, and should not be 
used as comparator for results of nonrandomised trials evaluating new treatment 
strategies. 
 
Defining prognostic groups  
Chapters 5 and 6 describe the results of tree modelling and decision analysis as 
alternative methods for creating classification groups.  
 
In Chapter 5 we evaluated the validity of a regression tree previously developed 
by the German Testicular Cancer group to identify subgroups within the IGCC 
poor prognosis group. 
Performance of this tree was substantially lower when applied to the IGCC data. 
We developed a new tree model, with similar methods as the tree developed by 
the German Testicular Cancer group, that differed in the selection and hierarchy 
of prognostic factors. Furthermore, internal validation of this new tree showed a 
large degree of optimism in performance. 
We conclude that regression tree analysis leads to unstable and optimistic models 
and is not an appropriate method for identifying subgroups within the group of 
poor prognosis patients. 
 
In Chapter 6 a decision-analytic approach was applied to determine how high the 
risk of patients with advanced testicular cancer should be in order to profit from 
high-dose chemotherapy with stem cell support.  
In the decision analysis both harm and benefit of treatment were weighed 
explicitly to determine a treatment threshold for the more intensive treatment.  
Benefit and harm were defined as the reduction and increase in absolute risk of 
mortality, including treatment related death and morbidity, due to high-dose 
chemotherapy. Estimates of benefit and harm were based on literature data, while 
using data from randomised controlled trials (RCT) would have been preferred. 
The decision analysis resulted in a treatment threshold of a 17% risk of cancer 
mortality. This threshold leads to a similar selection of patients as defined by the 
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IGCC classification for poor prognosis patients. Future results from RCTs should 
be used to update the analysis. 
 
This thesis ends with a discussion of the study results (Chapter 7), and 
conclusions and recommendations: 
 
• More complex classifications did not perform better than the relatively 
simple IGCC classification, which supports its validity as a method for 
distinguishing good, intermediate, and poor prognosis patients with 
advanced testicular cancer. 
 
• The previously reported IGCC classification survival estimates are too low 
for currently diagnosed patients with advanced testicular cancer. The 
results of nonrandomised trials should not be compared with the survival 
estimates as reported in 1997 by the IGCC investigators. Instead updated 
estimates adjusted for year of treatment or based on more recent 
literature should be used.  
 
• Decision analysis is an appropriate framework to define treatment 
thresholds in prognostic classifications. Tree models are recommended 
for exploratory purposes only. 
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In een prognostische classificatie worden patiënten met dezelfde eigenschappen 
gegroepeerd met als doel patiënten die verschillen in prognose te kunnen 
onderscheiden. Inzicht in het verwachte ziekteverloop van een patiënt kan de arts 
helpen bij het maken van een keuze tussen verschillende behandelmethodes. 
Het onderwerp van dit proefschrift is de evaluatie van methodologische aspecten 
bij de ontwikkeling van prognostische classificaties. We hebben ons daarbij 
gericht op patiënten met testiscarcinoom. Deze patiënten worden momenteel 
geclassificeerd in 3 groepen met een goede, gemiddelde of slechte prognose aan 
de hand van de ‘International Germ Cell Consensus (IGCC)’ classificatie. De 
IGCC classificatie wordt gebruikt ter ondersteuning van behandelingsbeslissingen 
en als methode om patiënten te selecteren voor klinische trials. 
Dit proefschrift heeft twee onderwerpen: (1) de validiteit van de IGCC 
classificatie: zijn de aannames die ten grondslag liggen aan de IGCC classificatie 
valide en kunnen de overlevingskansen zoals gerapporteerd door de IGCC 
classificatie worden gegeneraliseerd naar patiënten die nu met testiscarcinoom 
worden gediagnosticeerd, (2) zijn alternatieve methoden nuttig voor het 
bepalen van prognostische groepen, met name voor patiënten met een slechte 
prognose. 
 
Validiteit van de IGCC classificatie 
In Hoofdstuk 1 worden de belangrijkste methodologische aspecten bij de 
ontwikkeling van een prognostische classificatie besproken en wordt 
achtergrondinformatie over testiscarcinoom gegeven. 
Hoofdstukken 2, 3, en 4 gaan over de validiteit van de IGCC classificatie, te 
weten de aannames die gemaakt zijn bij de ontwikkeling van de IGCC 
classificatie (Hoofdstukken 2 en 3), en de generaliseerbaarheid van de 
overlevingskansen van de IGCC classificatie voor patiënten die nu worden 
gediagnosticeerd (Hoofdstukken 3 en 4). 
 
In de IGCC classificatie wordt aangenomen dat alle prognostische factoren even 
belangrijk zijn bij het voorspellen van de prognose van een patiënt. Verder, wordt 
er binnen een prognose groep geen onderscheid gemaakt tussen patiënten met 
een of meerdere prognostische factoren. In Hoofdstuk 2 wordt onderzocht in 
hoeverre het discriminerend vermogen van de IGCC classificatie verbeterd kan 
worden door rekening te houden met verschillen in voorspellende waarden 
tussen prognostische factoren en het aantal ongunstige prognostische factoren. 
Samenvatting 
 
161 
Het discriminerend vermogen van een prognostische classificatie geeft aan hoe 
goed een prognostische classificatie in staat is patiënten met een slechte 
prognose te onderscheiden van patiënten met een goede prognose.  
De validiteit is getoetst door alternatieve classificaties te ontwikkelen in de 
originele IGCC data (n=3048) op basis van Cox regressie analyses en het gebruik 
van regressiebomen en vervolgens het discriminerend vermogen van deze 
alternatieve classificaties te vergelijken met die van de IGCC classificatie.  
Beide methoden lieten verschillen zien in voorspellende waarde tussen de 
prognostische factoren in de IGCC classificatie. Tevens vonden we dat binnen 
een prognose groep het aantal ongunstige prognostische factoren van invloed is 
op de prognose van een patiënt. 
Dit resulteerde echter niet in een verbetering van het discriminerend vermogen 
ten opzichte van de IGCC classificatie. De IGCC classificatie is dus voldoende 
valide om groepen verschillend in prognose te onderscheiden. 
 
In de ontwikkeling van de IGCC classificatie werd 41% van de patiënten niet 
meegenomen in de analyses omdat hun gegevens niet compleet waren. De 
voornaamste reden hiervoor was dat de tumormarker LDH niet was vastgesteld. 
In Hoofdstuk 3 zijn de consequenties van het uitsluiten van deze patiënten op de 
geschatte overlevingskansen in de IGCC classificatie onderzocht door de 
ontbrekende gegevens in te vullen met een multipele imputatie techniek. 
Na imputatie van de ontbrekende gegevens, bleek dat de 
vijfjaarsoverlevingskansen lager waren voor patiënten met ontbrekende gegevens 
dan voor patiënten zonder ontbrekende gegevens. Dit verschil in overlevingskans 
kan als volgt verklaard worden. 
De kans op overleving voor patiënten met testiscarcinoom, en dus ook voor de 
patiënten in de IGCC data, is in de loop der tijd gestegen. Het jaar van 
behandeling van de patiënt is echter niet als prognostische factor meegenomen in 
de IGCC classificatie. Ook is er geen rekening gehouden met verbeteringen in 
behandelmethodes. 
Hierdoor zijn de door de IGCC gerapporteerde overlevingskansen te laag voor 
recenter behandelde patiënten. Omdat met name bij historische patiënten 
gegevens ontbraken, leidde multipele imputatie tot een verder onderschatting van 
de overlevingskansen in de IGCC classificatie, wanneer er niet werd gecorrigeerd 
voor jaar van behandeling. 
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In Hoofdstuk 4 werd onderzocht of de overlevingskansen van patiënten met 
testiscarcinoom verder zijn gestegen sinds de introductie van de IGCC 
classificatie in 1997. 
Een systematische inventarisatie van de literatuur leverde 10 studies op naar de 
overlevingskansen van patiënten met testiscarcinoom, geclassificeerd volgens de 
IGCC classificatie. Deze 10 studies beschreven 1775 patiënten, waarvan de 
overlevingskansen werden gecombineerd in een meta-analyse. 
De gecombineerde vijfjaarsoverlevingskansen waren 94, 83 en 71% voor 
patiënten met een goede, gemiddelde en slechte prognose respectievelijk. De 
originele IGCC classificatie rapporteerde lagere overlevingskansen (92, 80 en 
48%). Deze toename in overlevingskans voor patiënten met een slechte 
prognose kan verklaard worden door het gebruik van effectievere 
behandelmethodes en meer ervaring met het behandelen van patiënten met 
testiscarcinoom. 
 
Hoofdstukken 3 en 4 tonen aan dat de overlevingskansen zoals gerapporteerd 
door de IGCC classificatie niet valide zijn voor patiënten die op dit moment met 
testiscarcinoom gediagnosticeerd worden. Deze schattingen kunnen daarom ook 
niet gebruikt worden als referentie voor resultaten van niet gerandomiseerde trials 
om nieuwe behandelmethoden te vergelijken. 
 
Alternatieve methoden voor het bepalen van prognostische groepen 
Hoofdstukken 5 en 6 beschrijven in hoeverre besliskundige analyse en 
regressiebomen geschikte methodes zijn om prognostische groepen te definiëren.  
 
In Hoofdstuk 5 is de validiteit onderzocht van een regressieboom, ontwikkeld 
door de ‘German Testicular Cancer group’, die subgroepen binnen de slechte 
prognose groep van de IGCC classificatie onderscheidt. Het discriminerend 
vermogen van de regressieboom, dat wil zeggen het vermogen om patiënten met 
een goede en slechte prognose van elkaar te onderscheiden, was lager wanneer 
deze werd toegepast op de IGCC data. 
We ontwikkelden een nieuwe regressieboom volgens dezelfde principes als de 
regressieboom van de German Testicular Cancer group. In onze regressieboom 
werden andere prognostische factoren geselecteerd en werden de prognostische 
factoren anders geordend. Tenslotte, bleek uit interne validatie van de 
regressieboom dat het discriminerend vermogen te optimistisch is.  
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We concluderen dat het gebruik van regressiebomen leidt tot wisselvallige 
uitkomsten en een te optimistische inschatting van het discriminerend vermogen. 
Deze methode is daarom niet geschikt om subgroepen van patiënten binnen de 
slechte prognose van de IGCC classificatie te onderscheiden. 
 
In Hoofdstuk 6 werd een besliskundige analyse toegepast om te bepalen vanaf 
welk risico patiënten met testiscarcinoom zouden kunnen profiteren van hoge 
dosis chemotherapie met stamcelsupport in plaats van standaard dosis 
chemotherapie. 
In een besliskundige analyse worden de negatieve en de positieve effecten van 
een behandeling expliciet gewogen om een behandelingsdrempel te bepalen.  
Het positieve effect van een behandeling wordt gedefinieerd als de afname in het 
absolute risico op overlijden ten gevolgde van de behandeling; het negatieve 
effect als de stijging in het absolute risico op overlijden ten gevolge van de 
behandeling. Op basis van beschikbare literatuur is een schatting gemaakt van de 
positieve en negatieve effecten van hoge dosis chemotherapie. Idealiter worden 
hiervoor resultaten van gerandomiseerde klinische trials gebruikt. 
Op basis van de besliskundige analyse zouden patiënten met een risico van 17% 
of hoger om te overlijden aan kanker in aanmerking komen voor een behandeling 
met hoge dosis chemotherapie. Deze behandeldrempel leidt tot een vergelijkbare 
selectie van patiënten als het gebruik van de IGCC classificatie. 
Deze besliskundige analyse moet verder geactualiseerd worden aan de hand van 
de resultaten van gerandomiseerde klinische trials die betere schattingen van de 
positieve en negatieve effecten van hoge dosis chemotherapie mogelijk maken.  
Dit proefschrift eindigt met een discussie van de onderzoeksresultaten 
(Hoofdstuk 7), en een aantal conclusies en aanbevelingen: 
 
• Complexere classificaties zijn niet beter in het onderscheiden van 
prognostische groepen dan de relatief simpele IGCC classificatie. Dit 
ondersteunt de validiteit van de IGCC classificatie om testiscarcinoom 
patiënten met een goede, gemiddelde en slechte prognose van elkaar te 
onderscheiden. 
 
• De in de IGCC classificatie gerapporteerde overlevingskansen zijn te laag 
voor patiënten die tegenwoordig gediagnosticeerd worden met 
testiscarcinoom. De resultaten van niet gerandomiseerde klinische trials 
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mogen niet vergeleken worden met de overlevingskansen zoals die in 
1997 door de IGCC classificatie zijn gerapporteerd. In plaats daarvan 
moeten overlevingskansen gebruikt worden die zijn gecorrigeerd voor 
jaar van behandeling of die gebaseerd zijn op meer recente literatuur. 
 
• Een besliskundige analyse is een geschikte methode om te bepalen vanaf 
welk risico een alternatieve behandelbeslissing te rechtvaardigen is. 
Regressiebomen mogen alleen gebruikt worden voor exploratief 
onderzoek naar interacties tussen prognostische factoren. 
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